<SEC-DOCUMENT>0001193125-23-175501.txt : 20230627
<SEC-HEADER>0001193125-23-175501.hdr.sgml : 20230627
<ACCEPTANCE-DATETIME>20230627060531
ACCESSION NUMBER:		0001193125-23-175501
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230624
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230627
DATE AS OF CHANGE:		20230627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oric Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001796280
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471787157
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39269
		FILM NUMBER:		231043918

	BUSINESS ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 388-5600

	MAIL ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d462067d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oric="http://www.oricpharma.com/20230624" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-06-24_to_2023-06-24">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-06-24_to_2023-06-24">0001796280</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="oric-20230624.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-06-24_to_2023-06-24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-24</xbrli:startDate> <xbrli:endDate>2023-06-24</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-06-24_to_2023-06-24">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt:datemonthdayyearen">June&#160;24, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-06-24_to_2023-06-24">ORIC Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-06-24_to_2023-06-24">001-39269</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-06-24_to_2023-06-24">47-1787157</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-06-24_to_2023-06-24">240 E. Grand Ave</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-06-24_to_2023-06-24">2nd Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-06-24_to_2023-06-24">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-06-24_to_2023-06-24">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-06-24_to_2023-06-24">94080</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-06-24_to_2023-06-24">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-06-24_to_2023-06-24">388-5600</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-06-24_to_2023-06-24">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-06-24_to_2023-06-24">ORIC</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-06-24_to_2023-06-24" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 24, 2023, ORIC Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with the purchasers named therein (the &#8220;Purchasers&#8221;), for the private placement (the &#8220;Private Placement&#8221;) of (i) 9,285,710 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), at $7.00 per Share, and (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase 2,857,142 shares of Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $6.9999 per Pre-Funded Warrant. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company. The aggregate gross proceeds for the Private Placement will be approximately $85&#160;million, before deducting offering expenses, and the Private Placement is expected to close on June&#160;27, 2023, subject to customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from the proposed financing to fund the research and development of the Company&#8217;s clinical-stage product candidates and research programs and for working capital and general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement, the Purchasers agreed not to sell or transfer the Securities, and the Company&#8217;s executive officers and directors agreed not to sell or transfer any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, until the earlier of (i)&#160;the Company&#8217;s public release of the initial data readout of the Phase 1b clinical trial of <span style="white-space:nowrap">ORIC-114</span> following the date hereof and (ii)&#160;December&#160;31, 2023, subject to certain exceptions, including sales pursuant to any previously adopted Rule 10b5-1 trading plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the Purchase Agreement, the Company also agreed to file a registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on or before January&#160;31, 2024 (subject to certain exceptions) for purposes of registering the resale of the Shares (including the Warrant Shares), to use its commercially reasonable efforts to have such registration statement declared effective within the time period set forth in the Purchase Agreement, and to keep such registration statement effective for up to two years. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including for liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and other obligations of the parties. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such Purchase Agreement and are made as of specific dates; are solely for the benefit of the parties (except as specifically set forth therein); may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Purchase Agreement, instead of establishing matters as facts; and may be subject to standards of materiality and knowledge applicable to the contracting parties that differ from those applicable to the investors generally. Investors should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. The Purchasers represented that they were accredited investors within the meaning of Rule 501(a) of Regulation D and were acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were offered without any general solicitation by the Company or its representatives. The securities sold and issued in the Private Placement will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Purchase Agreement and the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement and the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The disclosures set forth in Item 1.01 above are incorporated in this Item 3.02. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;26, 2023, the Company issued a press release announcing that it has entered into the Purchase Agreement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d462067dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d462067dex101.htm">Securities Purchase Agreement, dated June&#160;24, 2023, by and among the Company and the Purchasers named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d462067dex991.htm">Press Release dated June&#160;26, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this report that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the completion of the Private Placement and the anticipated use of proceeds therefrom, and related to the anticipated filing of a registration statement to cover resales of the Shares and Warrant Shares. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the Private Placement. For a discussion of these and other factors, please refer to the Company&#8217;s annual report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022 as well as the Company&#8217;s subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">ORIC PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;27, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic Piscitelli</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dominic Piscitelli</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d462067dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i)&nbsp;SUCH
SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (ii)&nbsp;SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (ii) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH
TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (iv)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF
DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORIC PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant No.
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Original&nbsp;Issue&nbsp;Date:&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;],&nbsp;2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals, Inc. , a Delaware corporation (the &#147;<I>Company</I>&#148;), hereby certifies that, for good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, [&nbsp;&nbsp;&nbsp;&nbsp;] or its registered assigns (the &#147;<I>Holder</I>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of
[&nbsp;&nbsp;&nbsp;&nbsp;] shares of common stock, $0.0001 par value per share (the &#147;<I>Common Stock</I>&#148;), of the Company (each such share, a &#147;<I>Warrant Share</I>&#148; and all such shares, the &#147;<I>Warrant Shares</I>&#148;) at
an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in <U>Section</U><U></U><U>&nbsp;9</U> herein, the &#147;<I>Exercise Price</I>&#148;), upon surrender of this <I>Warrant to Purchase Common Stock</I>
(including any <I>Warrants to Purchase Common Stock</I> issued in exchange, transfer or replacement hereof, the &#147;<I>Warrant</I>&#148;) at any time and from time to time on or after the date hereof (the &#147;<I>Original Issue Date</I>&#148;),
subject to the following terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For purposes of this Warrant, the following terms shall have the following meanings:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;Affiliate&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, but
only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative meanings, &#147;controlled by&#148;, &#147;controlling&#148; and &#147;under common control with&#148;) means, with
respect to a Person, possession, direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other ownership interests, by contract
or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<I>Commission</I>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<I>Closing Sale Price</I>&#148; means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security
prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for
a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment
to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during the applicable calculation period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<I>Principal Trading Market</I>&#148; means
the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f) <I>&#147;Securities Purchase Agreement&#148;</I> means that certain Securities Purchase Agreement dated as of [&#149;], 2023. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<I>Trading Day</I>&#148; means any weekday on which the Principal Trading Market is normally open for trading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<I>Transfer Agent</I>&#148; means Computershare Trust Company, N.A., the Company&#146;s transfer agent and registrar for the Common
Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Issuance of Securities; Registration of Warrants</U>. The Warrant, as initially issued by the
Company, is offered and sold pursuant to the Securities Purchase Agreement. Accordingly, the Warrant and the Warrant Shares are &#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act. The Company shall register
ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<I>Warrant Register</I>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to
which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all
other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Registration of Transfers</U>. Subject to compliance with all applicable securities laws, the
Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<I>New Warrant</I>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the
transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any
New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any
notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Exercise and Duration of Warrants</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from
time to time on or after the Original Issue Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an
exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &#147;<I>Exercise Notice</I>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a &#147;cashless exercise&#148; if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the date on which the last of such items is delivered to the Company (as
determined in accordance with the notice provisions hereof) is an &#147;<I>Exercise Date</I>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise
Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The aggregate exercise price of this Warrant, except for the
Exercise Price, was <FONT STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or before the Original Issue Date, and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
consequently no additional consideration (other than the Exercise Price) shall be required to be paid by the Holder to effect any exercise of this Warrant. The Holder shall not be entitled to the
return or refund of all, or any portion, of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> exercise price under any circumstance or for any reason whatsoever. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Delivery of Warrant Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3)&nbsp;Trading Days after the Exercise Date),
upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company
(&#147;<I>DTC</I>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the &#147;<I>FAST Program</I>&#148;) or if the certificates are
required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#146;s share register in the name of the Holder
or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#147;Person&#148;) so designated by the Holder to receive Warrant
Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the certificates
evidencing such Warrant Shares, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) If by the close of the third (3rd) Trading Day after the Exercise Date, the
Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to credit the Holder&#146;s balance account with DTC for such
number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction, provided such purchases shall be made in a
commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<I><FONT
STYLE="white-space:nowrap">Buy-In</FONT></I>&#148;), then the Company shall, within three (3)&nbsp;Trading Days after the Holder&#146;s request and in the Company&#146;s sole discretion, either (1)&nbsp;pay in cash to the Holder an amount equal to
the Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#146;s obligation to deliver such certificate (and to issue such Warrant
Shares) shall terminate or (2)&nbsp;promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#146;s total
purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In</FONT> over the product of (A)&nbsp;the number of shares of Common Stock
purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date. The provisions of this Section&nbsp;5(b) shall be the only remedy available to the Holder in the
event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to Section&nbsp;5(a) and a <FONT STYLE="white-space:nowrap">Buy-In</FONT> occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to Section&nbsp;5(b), the Company&#146;s obligations to issue and deliver Warrant Shares in
accordance with and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver
or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or
any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in
connection with the issuance of Warrant Shares. Subject to Section&nbsp;5(b), nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Charges, Taxes and Expenses</U>. Issuance and delivery of certificates for shares of Common Stock upon
exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of
which taxes and expenses shall be paid by the Company; <I>provided, however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares
or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Replacement of Warrant</U>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in
exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case)
and, in each case, a customary and reasonable contractual indemnity and surety bond, if requested by the Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the
Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Reservation of Warrant Shares</U>. The Company
covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant
Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of
persons other than the Holder (taking into account the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the
applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to
assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be
listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Certain Adjustments</U>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while
this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, as described in the Securities Purchase Agreement, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock,
(iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such
case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock
outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or
distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and
thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii)&nbsp;of this paragraph shall become effective immediately after the
effective date of such subdivision or combination. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is
outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by Section&nbsp;9(a) or a distribution subject to
Section&nbsp;9(c)), (iii)&nbsp;rights or warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (other than a distribution pursuant to a Fundamental Transaction (as defined below) subject to Section&nbsp;9(c)) (in
each case, &#147;<I>Distributed Property</I>&#148;), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in
addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of
such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the
stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects
any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital
stock who tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than
the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such
Person immediately after the transaction), provided, however, that the forgoing shall not include transactions for which the primary purpose is raising capital, or (v)&nbsp;the Company effects any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by
<U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<I>Fundamental Transaction</I>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount
and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then
issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<I>Alternate Consideration&#148;</I>). The Company shall not effect any Fundamental Transaction in which the Company is not the
surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash, solely marketable securities, or a combination of cash and marketable securities, and the Company
provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to <U>Section</U>&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other
Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other
obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. In the event the Holder does not exercise this Warrant as contemplated by the
foregoing sentence, this Warrant shall be deemed exercised in full without regard to any limitations on exercise contained herein pursuant to the &#147;cashless exercise&#148; provision in Section&nbsp;10 hereof upon the effective date of the
consummation of such Fundamental Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise
Price pursuant to <U>Section</U><U></U><U>&nbsp;9</U>, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price
payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted
below the par value of the Common Stock then in effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;9</U>
shall be made to the nearest <FONT STYLE="white-space:nowrap">one-tenth</FONT> of one cent or the nearest share, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in
accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this
Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the
Holder and to the Company&#146;s transfer agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company
(i)&nbsp;declares a dividend or any other pro rata distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of
the Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up
of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such
transaction at least ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; <I>provided, however</I>, that the
failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In the event such notice and the contents thereof shall be deemed to constitute material <FONT
STYLE="white-space:nowrap">non-public</FONT> information, the Company shall (on the same time frame set forth in the immediately prior sentence) offer the Holder the ability to sign a confidentiality agreement related thereto sufficient to allow the
Holder to receive such notice, and the Company shall deliver such notice immediately upon execution of such confidentiality agreement. If the holder does not sign the confidentiality agreement, then the Holder shall not receive such notice. In
addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(c)</U>,
other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is
consummated. Holder agrees to maintain any information disclosed pursuant to this Section&nbsp;9(g) in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company&#146;s
securities following receipt any such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Payment of Exercise Price</U>. Notwithstanding anything contained herein to the contrary, the
Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise&#148;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected
pursuant to Section&nbsp;3(a)(9) of the Securities Act, as determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares
to be issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price of the shares of Common Stock (as reported by Bloomberg Financial Markets) as of the Trading Day on the date
immediately preceding the Exercise Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect for the applicable Warrant Shares
at the time of such exercise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged
that the Warrant Shares issued in a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was
originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant Shares is, for any reason, not
effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this Section&nbsp;10. Except as set forth in Section&nbsp;5(b) <FONT STYLE="white-space:nowrap">(Buy-In</FONT>
remedy) and Section&nbsp;12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.
<U>Limitations on Exercise</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) Any Holder of Warrants shall be prohibited from exercising the Holder&#146;s Warrants if, immediately
prior to or following such exercise (or portion of such exercise thereof), the Holder, together with its Affiliates and any member of a Section&nbsp;13(d) group, beneficially owns or would beneficially own as determined in accordance with
Section&nbsp;13(d) of the U.S. Securities Exchange Act of 1934, as amended, and the rules thereunder (the &#147;Exchange Act&#148;) more than 9.99% (the &#147;Beneficial Ownership Limitation&#148;) of the issued and outstanding Common Stock or any
other class of equity security (other than an exempted security) of the Company that is registered pursuant to Section&nbsp;12 of the Exchange Act. For purposes of calculating beneficial ownership, the aggregate number of shares of Common Stock
beneficially owned by the Holder, together with its affiliates and any member of the Section&nbsp;13(d) group, shall include the number of shares of Common Stock issuable upon exercise of the relevant Warrants with respect to which the determination
is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i)&nbsp;conversion of the remaining, unconverted Warrants beneficially owned by a Holder, together with its Affiliates and any member of
Section&nbsp;13(d) group, and (ii)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Holder, together with its Affiliates and any member of Section&nbsp;13(d)
group (including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous to the limitation contained herein. For purposes of this Paragraph 11(a), beneficial
ownership and whether a Holder is a member of a Section&nbsp;13(d) group shall be calculated and determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder, it being acknowledged and agreed that the
Holder is solely responsible for any schedules required to be filed in accordance therewith. For purposes of the Warrants, in determining the number of outstanding shares of Common Stock, a Holder of Warrants may rely on the number of outstanding
shares of Common Stock as reflected in (1)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT>
or other public filing with the Securities and Exchange Commission, as the case may be, (2)&nbsp;a more recent public announcement by the Company, or (3)&nbsp;any other notice by the Company or the Company&#146;s transfer agent setting forth the
number of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request of a Holder of Warrants, the Company shall within two (2)&nbsp;Business Days confirm to such Holder the number of shares of Common Stock then
outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that it, its Affiliates or any member of a Section&nbsp;13(d) group owns and has the right to acquire through the exercise of derivative securities and any
limitations on exercise or conversion analogous to the limitation contained herein contemporaneously or immediately prior to exercising the relevant Warrant. Any purported delivery of any number of shares of Common Stock or any other security upon
exercise of Warrants shall be void and have no effect to the extent, but only to the extent, that before or after such delivery, the exercising Holder, together with its Affiliates and any member of a Section&nbsp;13(d) group would have beneficial
ownership in excess of the Beneficial Ownership Limitation. By written notice to the Company, a Holder of Warrants may from time to time increase or decrease the Beneficial Ownership Limitation to any other percentage not in excess of 19.99%
specified in such notice; provided that any increase in the Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not restrict the number of shares of Common Stock which a Holder may receive or
beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in <U>Section</U><U></U><U>&nbsp;9(c)</U> of this Warrant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>No Fractional Shares</U>. No fractional Warrant Shares will be issued in connection with any exercise
of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on
the Closing Sale Price) for any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Notices</U>. Any and all notices or other communications or deliveries hereunder
(including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via confirmed <FONT
STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the Transfer Agent prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day
after the date of transmission, if such notice or communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the
Transfer Agent on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next
business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>Warrant
Agent</U>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be
merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or
stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to
vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this
Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In
addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are
asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to
by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares
above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and
Assigns</U>. Subject to the restrictions on transfer set forth in this Warrant and compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of
the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any
legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived
with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS
CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.
EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY
CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY
MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS
AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or
affect any of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid
or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a
valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ORIC PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE 1 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF EXERCISE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be
executed by the Holder to purchase shares of Common Stock under the Warrant] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of Warrant No. __ (the &#147;<I>Warrant</I>&#148;) issued by ORIC Pharmaceuticals, Inc., a Delaware corporation (the
&#147;<I>Company</I>&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2)
The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price
shall be made as (check one): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
immediately available funds to the Company in accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise Notice, the Company shall deliver
to the Holder Warrant Shares determined in accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this Exercise Notice, the undersigned
represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the
Securities Exchange Act of 1934, as amended) permitted to be owned under <U>Section</U><U></U><U>&nbsp;11(a)</U> of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Holder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d462067dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORIC PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This<B> Securities Purchase Agreement</B> (the &#147;<B><I>Agreement</I></B>&#148;) is made as of June&nbsp;24, 2023 (the
&#147;<B><I>Effective Date</I></B>&#148;), by and among <B>ORIC Pharmaceuticals, Inc.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and the purchasers whose names and addresses are set forth on the signature pages hereof
(each, a &#147;<B><I>Purchaser</I></B>&#148; and, collectively, the &#147;<B><I>Purchasers</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Purchasers
desire to purchase, and the Company has agreed to sell, 9,285,710 shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;<B><I>Common Stock</I></B>&#148;) and 2,857,142 <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants to purchase Common Stock in the form attached hereto as <U>Exhibit A</U> (the &#147;<B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</I></B>&#148;), for a purchase price of $7.00 per share and $6.9999 per <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and aggregate gross proceeds to the Company of approximately $85&nbsp;million. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Purchasers hereby agree, severally and not jointly,
as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;1 AUTHORIZATION OF SALE OF SECURITIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized the sale and issuance of shares of its Common Stock and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants
to the Purchasers on the terms and subject to the conditions set forth in this Agreement. The shares of Common Stock that may be sold to the Purchasers hereunder at the Closing (as defined in <U>Section</U><U></U><U>&nbsp;3.1</U>) shall be referred
to as the &#147;<B><I>Shares</I></B>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;2 AGREEMENT TO SELL AND PURCHASE THE SHARES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Purchase</U>. At the Closing, the Company will issue, sell and deliver to each Purchaser, and such Purchaser will purchase from the
Company, that number of Shares and/or <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants set forth opposite such Purchaser&#146;s name on <U>Schedule A</U> hereto, for the purchase price set forth therein (the &#147;<B><I>Purchase
Price</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Definitions</U>. For purposes of this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Affiliate</I></B>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act (as defined in <U>Section</U><U></U><U>&nbsp;4.3</U> below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Business Day</I></B>&#148; means a day, other than a Saturday or Sunday, on which banks in New York City are open for the
general transaction of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Law</I></B>&#148; means any federal, state, local or foreign law (including common law),
statute, code, ordinance, rule, regulation, order, judgment, writ, stipulation, award, injunction, decree, arbitration award or finding or any other legally enforceable requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Material Adverse Effect</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.1</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Person</I></B>&#148; means an individual, corporation, partnership, limited
liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Securities</I></B>&#148; means the Shares, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Warrant
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Trading Market</I></B>&#148; means the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Warrant Shares</I></B>&#148; means the shares of Common Stock issuable upon exercise of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;3 CLOSING, CLOSING CONDITIONS AND CLOSING DELIVERIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Closing</U>. The closing of the purchase and sale of the Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants pursuant
to this Agreement (the &#147;<B><I>Closing</I></B>&#148;) shall occur no later than 5:00 p.m., Pacific time, on June&nbsp;27, 2023, subject to the satisfaction or waiver of all of conditions set forth in <U>Section</U><U></U><U>&nbsp;3.2</U> and the
delivery of all of the closing deliveries set forth in <U>Section</U><U></U><U>&nbsp;3.3</U> (such date, the &#147;<B><I>Closing Date</I></B>&#148;), at the offices of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C., 650 Page Mill Road, Palo Alto,
CA 94304, or at such other time and place as may be agreed to by the Company and the Purchasers. At or prior to the Closing, each of the Company and the Purchasers shall execute any related agreements or other documents required hereunder to be
executed as of the Closing hereunder, each dated as of the date of the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Closing Conditions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Mutual Closing Condition</U>. There shall have been no Law enacted, entered, promulgated, enforced or deemed applicable by any
governmental authority of competent jurisdiction that is in effect and makes illegal or otherwise prohibits or materially delays the consummation of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Conditions to Purchaser</U><U>&#146;</U><U>s Obligations</U>. Each Purchaser&#146;s obligation to purchase the Shares and/or <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (as applicable) at the Closing is subject to the fulfillment, on or before the Closing, of each of the following conditions, unless waived: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company&#146;s representations and warranties in <U>Section</U><U></U><U>&nbsp;4</U> shall be true and correct in all material
respects at the date of the Closing, with the same force and effect as if they had been made on and as of the date of the Closing, other than the representations and warranties set forth in <U>Sections 4.1</U>, <U>4.2</U>, <U>4.3</U>, <U>4.5</U>,
<U>4.8</U>, <U>4.9</U>, and <U>4.14</U>, which shall be true and correct in all respects as if they had been made on and as of the date of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Company shall have performed and complied with in all material respects all agreements and conditions herein required to be
performed or complied with by the Company on or before the Closing, or any breach or failure to do so has been cured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) There shall
have been no Material Adverse Effect with respect to the Company since the date hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Conditions to the Company&#146;s Obligations</U>. The Company&#146;s obligation to
issue and sell the Securities at the Closing to a Purchaser is subject to the fulfillment, on or before the Closing, of each of the following conditions, unless waived: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Such Purchaser&#146;s representations and warranties in <U>Section</U><U></U><U>&nbsp;5</U> shall be true and correct in all material
respects at the date of the Closing, with the same force and effect as if they had been made on and as of said date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Such Purchaser
shall have performed and complied with in all material respects all agreements and conditions herein required to be performed or complied with by it on or before the Closing, or any breach or failure to do so has been cured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Closing Deliveries</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Payment of the Purchase Price at Closing</U>. At the Closing, each Purchaser shall deliver, or cause to be delivered, to the Company,
an amount equal to the Purchase Price by wire transfer of immediately available funds to the Company&#146;s account pursuant to wire instructions set forth in <U>Schedule B</U>. Each Purchaser&#146;s obligations to pay the Purchase Price shall be
several and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Issuance of the Securities at the Closing</U>. At the Closing, the Company shall issue, or cause the
Company&#146;s transfer agent to issue, to each Purchaser through a book-entry account maintained by the Company&#146;s transfer agent the number of Shares purchased by such Purchaser, as set forth in <U>Schedule A</U> hereto, at the Closing against
payment by such Purchaser of the Purchase Price. Such Shares shall be appropriately legended as set forth in <U>Section</U><U></U><U>&nbsp;5.11</U> herein. For each Purchaser of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the
Company shall deliver a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant registered in the name of such Purchaser to purchase up to the number of Warrant Shares as set forth in <U>Schedule A</U> hereto, with an exercise price equal to
$0.0001, subject to adjustment as provided therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Secretary&#146;s Certificate</U>. At the Closing, the Purchasers shall have
received a certificate signed by the Secretary of the Company, certifying the resolutions of the Board of Directors of the Company or a duly authorized committee thereof approving this Agreement and all of the transactions contemplated hereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Compliance Certificate</U>. At the Closing, the Purchasers shall have received a certificate signed by the President and Chief
Executive Officer of the Company certifying to the fulfillment of the conditions set forth in <U>Section</U><U></U><U>&nbsp;3.2(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Opinion</U>. At the Closing, the Purchasers shall have received an opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C., counsel
for the Company, dated as of the Closing Date, in a form reasonably satisfactory to the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</U>. At the Closing, the Purchasers shall have received executed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, dated as of the date hereof, by and among the Company and the
directors and officers of the Company listed on <U>Schedule C</U> hereto, in the form attached hereto as <U>Exhibit B</U>, which <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement may only be waived by the Company upon receipt of written
consent of the Purchasers holding at least a majority of the Securities then held by all Purchasers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;4 REPRESENTATIONS AND WARRANTIES OF
THE COMPANY. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as disclosed in the SEC Documents (as defined in <U>Section</U><U></U><U>&nbsp;4.4</U> below), the Company hereby
represents and warrants to the Purchasers as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Organization and Standing; Subsidiaries</U>. The Company has been duly
incorporated or organized and is validly existing and in good standing under the laws of Delaware or other jurisdiction of incorporation or organization, has full corporate or other power and authority necessary to own or lease its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and in good standing in all jurisdictions in which the character of the property owned
or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have resulted in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability of this
Agreement, (ii)&nbsp;a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company, or (iii)&nbsp;a material adverse effect on the Company&#146;s ability to perform on a timely basis
its material obligations under this Agreement with respect to Closing (any of (i), (ii) or (iii), a &#147;<B><I>Material Adverse Effect</I></B>&#148;). The Company does not own, directly or indirectly, any shares of stock or any other equity or
long-term debt securities of any corporation or have any equity interest in any corporation, firm, partnership, joint venture, association or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Corporate Power; Authorization</U>. The Company has all requisite corporate power, and the Company and its Board of Directors have
taken all requisite corporate action, to authorize, execute and deliver this Agreement, to consummate the transactions contemplated herein and therein, including to sell, issue and deliver the Securities to the Purchasers, and to carry out and
perform all of the Company&#146;s obligations hereunder and thereunder. This Agreement constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by
applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally and (ii)&nbsp;as limited by equitable principles generally, including any specific
performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Issuance and Delivery of the Securities</U>. The Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants have been duly authorized and, when issued and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable. The Warrant Shares have been duly and validly authorized and reserved for
issuance and, upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, in accordance with their terms, including the payment of any exercise price therefor, will be validly issued, fully paid and nonassessable. The issuance
and delivery of the Securities is not subject to preemptive, <FONT STYLE="white-space:nowrap">co-sale,</FONT> right of first refusal or any other similar rights of the stockholders of the Company or any other Person or any liens or encumbrances,
other than encumbrances under applicable securities laws. Assuming the accuracy of the representations made by the Purchasers in <U>Section</U><U></U><U>&nbsp;5</U>, the offer and issuance by the Company of the Securities is exempt from registration
under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>SEC Documents; Financial Statements;
Independent Accountants</U>. The Company is not an &#147;ineligible issuer&#148; (as defined in Rule 405 promulgated under the Securities Act). The Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended
(the &#147;<B><I>Exchange Act</I></B>&#148;), and has filed or will file in a timely manner all documents that the Company was or is required to file with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) under
Sections 13, 14(a) and 15(d) of the Exchange Act, since becoming subject to the requirements of the Exchange Act (the foregoing documents (together with any documents filed by the Company under the Exchange Act, whether or not required) being
collectively referred to herein as the &#147;<B><I>SEC Documents</I></B>&#148;). As of their respective filing dates (or, if amended prior to the date of this Agreement, when amended), all SEC Documents complied in all material respects with the
requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder. None of the SEC Documents as of their respective filing dates contained any untrue statement of material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company set forth in the SEC Documents (the
&#147;<B><I>Financial Statements</I></B>&#148;) comply in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto. The Financial Statements have been prepared
in accordance with United States generally accepted accounting principles consistently applied and fairly present the financial position of the Company at the dates thereof and the results of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal, recurring adjustments). The accountants who certified the Financial Statements are independent public accountants as required by the Securities Act and the Exchange Act and the regulations
thereunder and the Public Company Accounting Oversight Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>Capitalization</U>. As set forth in the SEC Documents as of the date set forth
therein, all of the Company&#146;s outstanding shares of capital stock have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and were not issued
in violation of or subject to any preemptive right or other rights to subscribe for or purchase securities. Except as disclosed in the SEC Documents, there are no existing options, warrants, calls, subscriptions or other rights, agreements,
arrangements or commitments of any character, relating to the issued or unissued capital stock of the Company, obligating the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred,
sold, redeemed, purchased, repurchased or otherwise acquired any capital stock or voting debt of, or other equity interest in, the Company or securities or rights convertible into or exchangeable for such shares or equity interests or obligations of
the Company to grant, extend or enter into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment. Neither the execution of this Agreement nor the issuance of Common Stock or other securities pursuant to
any provision of this Agreement will give rise to any preemptive rights or rights of first refusal on behalf of any Person or result in the triggering of any anti-dilution or other similar rights. Other than the Common Stock, there are no other
shares of any other class or series of capital stock of the Company issued or outstanding. The Company&#146;s Certificate of Incorporation, as amended and as in effect on the date hereof (the &#147;<B><I>Certificate of Incorporation</I></B>&#148;),
or the Company&#146;s Bylaws, as amended and as in effect on the date hereof (the &#147;<B><I>Bylaws</I></B>&#148;), are included in the SEC Documents, and the Company shall not amend or otherwise modify the Certificate of Incorporation or Bylaws
prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Litigation</U>. There are no legal or governmental actions, suits or other proceedings pending or, to the
knowledge of the Company, threatened against the Company, before or by any court, regulatory body or administrative agency or any other governmental agency or body, domestic or foreign, which actions, suits or proceedings, individually or in the
aggregate, would reasonably be expected to (a)&nbsp;challenge this Agreement or prohibit or delay the transactions contemplated herein or (b)&nbsp;have a Material Adverse Effect. The Company is not a party to or subject to the provisions of any
injunction, judgment, decree or order of any court, regulatory body, administrative agency or other governmental agency or body that might have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Governmental Consents</U>. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state, or local governmental authority or the Trading Market on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement except for the filing of a Form D
with the Commission under the Securities Act and compliance with the securities and blue sky laws in the states and other jurisdictions in which shares of Common Stock are offered and/or sold, which compliance will be effected by the Company in
accordance with such laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8 <U>No Default or Consents</U>. The Company is not in violation or default under its organizational
documents. Neither the execution, delivery or performance of this Agreement by the Company nor the consummation of any of the transactions contemplated hereby (including the issuance, sale and delivery by the Company of the Shares and <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the reservation for issuance and issuance of the Warrant Shares) will: (i)&nbsp;give rise to a right to terminate or accelerate the due date of any payment due under, or conflict with or result
in the breach of any term or provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under, or require any consent or waiver under, or result in the execution or imposition of any
lien, charge or encumbrance upon any properties or assets of the Company pursuant to the terms of any indenture, mortgage, deed of trust or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other agreement or instrument to which the Company is a party or by which any of its respective properties or business is bound, or any franchise, license, permit, judgment, decree, order,
statute, rule or regulation (including federal and state securities laws and regulations) and the rules and regulations, assuming the correctness of the representations and warranties made by the Purchasers herein, of any self-regulatory
organization to which the Company or its securities are subject, applicable to the Company, or (ii)&nbsp;violate or conflict with any provision of the Certificate of Incorporation or the Bylaws, except in the case of clause (i)&nbsp;as would not
cause, either individually or in the aggregate, a Material Adverse Effect, and except for such consents or waivers which have already been obtained and are in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>No Material Adverse Change</U>. Since December&nbsp;31, 2022, there have been no events, occurrences or developments that have had or
would reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. Except for the transactions contemplated by this Agreement, no event, liability or development has occurred or exists with respect to the
Company or its business, properties, operations or financial conditions that would be required to be disclosed by the Company under applicable securities laws at the Effective Date that has not been publicly disclosed at least one Business Day prior
to the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10 <U>No General Solicitation</U>. Neither the Company, nor any of its Affiliates, nor any Person acting on its
or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection with the offer or sale of the Shares and
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11 <U>No Integrated Offering</U>. None of the Company or any of its
Affiliates, or any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of any of the Shares and <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants under the Securities Act or cause this offering of the Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be integrated with prior offerings by the Company for purposes of
the Securities Act or any applicable stockholder approval provisions, including under the rules and regulations of the Trading Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12 <U>Sarbanes-Oxley Act</U>. The Company is in material compliance with the requirements of the Sarbanes-Oxley Act of 2002 that are
effective and applicable to the Company as of the date hereof, and the rules and regulations promulgated by the Commission thereunder that are effective and applicable to the Company as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.13 <U>Intellectual Property</U>. To the knowledge of the Company, the Company owns, possesses, licenses or has rights to use, on terms that
the Company believes to be reasonable, all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses, trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and other similar rights
that are necessary or material for use in connection with the business of the Company as described in the SEC Documents (collectively, the &#147;<B><I>Intellectual Property Rights</I></B>&#148;), except where the failure to own, possess or license
such rights would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company has not received written notice alleging the Intellectual Property Rights used by the Company violates or infringes upon
the rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company has taken reasonable
security measures to protect the secrecy and confidentiality of the Intellectual Property Rights, where applicable, except where the failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14 <U>Disclosure</U>. The Company understands and confirms that the Purchasers will rely
on the representations, warranties and covenants set forth in this <U>Section</U><U></U><U>&nbsp;4</U> in effecting the transactions contemplated by this Agreement. To the knowledge of the Company, all due diligence materials regarding the Company
and its business and the transactions contemplated hereby (including the information referred to in <U>Section</U><U></U><U>&nbsp;5.8</U> hereof), furnished by or on behalf of the Company to the Purchasers upon their request are, when taken together
with the SEC Documents, true and correct in all material respects and do not contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements made therein, in light of the circumstances in
which they were made, misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15 <U>Properties and Assets</U>. The Company does not own any real property and has good and
marketable title to all other property and assets described as owned by it in the latest Financial Statements set forth in the SEC Documents, free and clear of all liens, pledges or encumbrances of any kind except (a)&nbsp;those, if any, reflected
in such Financial Statements or (b)&nbsp;those that are not material in amount and do not adversely affect the use made and proposed to be made of such property by the Company. The Company holds its leased properties under valid and binding leases,
except as would not have a Material Adverse Effect. The Company owns or leases all such properties as are materially necessary to their respective operations as now conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.16 <U>Compliance and Regulatory</U>. The Company is in compliance with all applicable laws, rules and regulations of the jurisdictions in
which it conducts its business, including all applicable local, state and federal environmental laws and regulations, and all applicable laws, rules and regulations enforced by the United States Food and Drug Administration (the
&#147;<B><I>FDA</I></B>&#148;) (including the Federal Food, Drug And Cosmetic Act of, as amended, and the regulations promulgated thereunder) or any applicable laws enforced by equivalent governmental agency outside the United States, except where
failures to be so in compliance, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Any preclinical studies or clinical trials conducted by or, to the Company&#146;s knowledge, on behalf of the
Company (the &#147;<B><I>Studies</I></B>&#148;), were and, if still pending, are being and shall continue to be, conducted in all material respects in accordance all applicable laws and regulations governing the conduct of such Studies. The Company
has not received any written notice from the FDA or any other governmental agency or institutional review board exercising comparable authority requiring the termination, suspension, or clinical hold of Studies, where such termination, suspension or
clinical hold would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.17 <U>Taxes</U>. The Company has filed on a timely basis
(giving effect to extensions) all required federal, state and foreign income and franchise tax returns and have timely paid or accrued all taxes shown as due thereon, including interest and penalties, except where the failure to timely file any
returns or pay such taxes would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and, to the knowledge of the Company, there is no tax deficiency that has been or might be asserted or threatened
against it or them that would have a Material Adverse Effect. All tax liabilities accrued through the date hereof have been adequately provided for on the books of the Company. There are no liens for material taxes upon the assets of the Company
other than for current taxes not yet due and payable or for taxes that are being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP has been made in the Company&#146;s most recent financial
statements included in the SEC Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.18 <U>Investment Company</U>. The Company is not, and immediately after receipt of payment
for the Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants will not be, an &#147;investment company&#148; or an &#147;affiliated person&#148; of, or &#147;promoter&#148; or &#147;principal underwriter&#148; for an investment
company, within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.19 <U>Insurance</U>. The Company maintains insurance underwritten by insurers of recognized financial responsibility, of the types and in
the amounts that the Company reasonably believes is adequate for its business, including directors&#146; and officers&#146; liability insurance, all of which insurance is in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.20 <U>Price of Common Stock</U>. The Company has not taken, and will not take, directly or
indirectly, any action designed to cause or result in, or that has constituted or that might reasonably be expected to constitute, the stabilization or manipulation of the price of the shares of the Common Stock to facilitate the sale or resale of
the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.21 <U>Governmental Permits, Etc</U>. The Company has all franchises, licenses, permits, certificates and other
authorizations from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of its business as currently conducted, including, without limitation, all such certificates,
approvals, authorizations, exemptions, licenses and permits required by the FDA or any other comparable governmental agencies (collectively, &#147;<B><I>Permits</I></B>&#148;), except where the failure to possess such Permits would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect. The Company has not received any written notice requiring or threatening any revocation or modification of any such Permits, where such revocation or modification would
reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.22 <U>Internal Control over Financial Reporting</U>. The Company maintains
internal control over financial reporting (as such term is defined in paragraph (f)&nbsp;of Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the Exchange Act) as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> under the
Exchange Act. To the knowledge of the Company, since the end of the Company&#146;s most recent audited fiscal year, there has been no material weakness in the design or operation of the Company&#146;s internal control over financial reporting
(whether or not remediated) which are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.23 <U>Foreign Corrupt Practices</U>. Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee or
other Person acting on behalf of the Company, has, in the course of its actions for, or on behalf of, the Company (a)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (b)&nbsp;made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (c)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977,
as amended; or (d)&nbsp;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.24 <U>Employee Relations</U>. No material labor dispute with the employees of the Company, or with the employees of any principal supplier,
manufacturer, customer or contractor of the Company, exists or, to the Company&#146;s knowledge, is threatened or imminent. No executive officer of the Company (as defined in Rule 501(f) promulgated under the Securities Act) has notified the Company
that such officer intends to leave the Company or otherwise terminate such officer&#146;s employment with the Company. To the knowledge of the Company, no executive officer of the Company is, or is now expected to be, in violation of any material
term of any employment contract, confidentiality, disclosure or proprietary information agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, or any other agreement or any restrictive covenant involving or otherwise affecting
such executive officer&#146;s relationship with the Company, and the continued employment of each such executive officer does not subject the Company to any material liability with respect to any of the foregoing matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.25 <U>ERISA</U>. The Company is in compliance in all material respects with all presently applicable provisions of the Employee Retirement
Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;<B><I>ERISA</I></B>&#148;); no &#147;reportable event&#148; (as defined in ERISA) has occurred with respect to any &#147;pension
plan&#148; (as defined in ERISA) for which the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would have any material liability; the Company has not incurred or expects to incur material liability under (a)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any
&#147;pension plan&#148; or (b)&nbsp;Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the &#147;<B><I>Code</I></B>&#148;); and each &#147;Pension Plan&#148;
for which the Company would have liability that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified in all material respects and to the knowledge of the Company, nothing has occurred, whether by action or by failure to
act, which would cause the loss of such qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.26 <U>Registration Rights and Other Stockholder Agreements</U>. No Person has
any right to cause the Company to effect the registration under the Securities Act covering the transfer of any securities of the Company and there are no other stockholders agreements, voting agreements or other similar agreements with respect to
the Company&#146;s capital stock to which the Company is a party or, to the Company&#146;s knowledge, between or among any of the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.27 <U>Trading Market Compliance</U>. The Company has not, in the previous twelve (12)&nbsp;months, received (i)&nbsp;written notice from the
Trading Market that the Company is not in compliance with the listing or maintenance requirements of the Trading Market that would result in immediate delisting or (ii)&nbsp;any notification, Staff Delisting Determination, or Public Reprimand Letter
(as such terms are defined in applicable listing rules of the Trading Market) that requires a public announcement by the Company of any noncompliance or deficiency with respect to such listing or maintenance requirements. The Company is in
compliance with all listing and maintenance requirements of the Trading Market on the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.28 <U>No &#147;Bad Actor&#148;
Disqualification</U>. No &#147;bad actor&#148; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a &#147;<B><I>Disqualification Event</I></B>&#148;) is applicable to the Company or, to the knowledge of the Company, any
Company Covered Person (as defined below), except for a Disqualification Event to which Rule <FONT STYLE="white-space:nowrap">506(d)(2)(ii-iv)</FONT> or (d)(3) is applicable. &#147;<B><I>Company Covered Person</I></B>&#148; means, with respect to
the Company as an &#147;issuer&#148; for purposes of Rule 506 promulgated under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.29 <U>OFAC</U>. None of the Company or, to the knowledge of the Company, any director, officer, agent, employee or Affiliate of the Company
is a Person, or is more than 50&nbsp;percent owned in the aggregate by or acting on behalf of one or more Persons that are, currently the target of any sanctions administered or enforced by the United States Government, including, without
limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, HM Treasury, or other relevant sanctions authority (collectively, &#147;<B><I>Sanctions</I></B>&#148;),
nor is the Company located, organized or resident in a country or territory that is the subject of comprehensive country-wide or territory-wide Sanctions; and the Company will not directly or knowingly indirectly use the proceeds of the sale of the
Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business (i)&nbsp;with any Person, or in any country or territory, that, at the time
of such funding, is a designated target of Sanctions, (ii)&nbsp;in a country or territory which at the time of such funding is the subject of comprehensive country-wide or territory-wide Sanctions, or (iii)&nbsp;in any other manner that will result
in a violation by any Person (including any Person participating in the transaction, whether as advisor, investor or otherwise) of Sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;5 REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Purchaser, severally and not jointly, represents and warrants to the Company that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Risk</U>. Such Purchaser, taking into account the personnel and resources it can practically bring to bear on the purchase of the
Securities contemplated hereby, is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
presenting an investment decision like that involved in the purchase of the Securities, including investments in securities issued by the Company, and has requested, received, reviewed and
considered all information the Purchasers know about and deem relevant (including the SEC Documents) in making an informed decision to purchase the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Purchase for Investment</U>. Purchaser is acquiring the Securities pursuant to this Agreement for its own account for investment only
and with no present intention of distributing any of such Securities or any arrangement or understanding with any other Persons regarding the distribution of such Securities, except in compliance with <U>Section</U><U></U><U>&nbsp;5.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Reliance</U>. Such Purchaser understands that the Securities are being offered and sold to it in reliance upon specific exemptions from
the registration requirements of the Securities Act, the Rules and Regulations and state securities laws and that the Company is relying upon the truth and accuracy of, and such Purchaser&#146;s compliance with, the representations, warranties,
agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. If any of the representations deemed to have
been made by it by its purchase of the Securities are no longer accurate prior to Closing, the Purchaser shall promptly notify the Company. If such Purchaser is acquiring the Securities as a fiduciary or agent for one or more investor accounts, it
represents that it has sole investment discretion with respect to each such account and it has full power to make the foregoing representations, acknowledgements and agreements on behalf of such account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Compliance with the Securities Act</U>. Such Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise
dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the securities purchased hereunder except in compliance with the Securities Act, applicable blue sky laws, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Accredited Investor</U>. Such Purchaser is an &#147;accredited investor&#148; within the meaning of Rule 501 of
Regulation D promulgated under the Securities Act or a Qualified Institutional Buyer within the meaning of Rule 144A promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Power and Authority</U>. Such Purchaser has all requisite corporate power, and has taken all requisite corporate action, to authorize,
execute and deliver this Agreement and each of the other agreements and instruments contemplated herein to which the Purchaser is a party, to consummate the transactions contemplated herein and therein and to carry out and perform all of such
Purchaser&#146;s obligations hereunder and thereunder. Upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of such Purchaser, enforceable in accordance with its terms, except (i)&nbsp;as
limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors&#146; rights generally and (ii)&nbsp;as limited by equitable principles generally, including any specific
performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Broker Dealer</U>. Such Purchaser is not a broker or dealer registered pursuant to Section&nbsp;15 of the Exchange
Act (a &#147;<B><I>Registered Broker Dealer</I></B>&#148;) and is not an Affiliate of a Registered Broker Dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Sophisticated
Investor</U>. Such Purchaser acknowledges that it is a sophisticated investor engaged in the business of assessing and assuming investment risks with respect to securities, including securities such as the Securities being offered hereby. Such
Purchaser further acknowledges that it is aware of the restrictions imposed by United States securities laws on the purchase or sale of securities by any Person who has received material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information from the issuer of such securities and on the communication of such information to any other Person when it is reasonably foreseeable that such other Person is likely to purchase or sell such securities in reliance upon such information.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Other Securities Transactions</U>. Such Purchaser has not, either directly or
indirectly through an Affiliate, agent or representative of the Company, engaged in any transaction in the securities of the Company other than with respect to the transactions contemplated herein, since the time that the Purchaser was first
contacted by the Company or any other Person regarding the transactions contemplated hereby until the date hereof, except as set forth in filings made with the Commission pursuant to the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Independent Advice</U>. Such Purchaser understands that nothing in this Agreement or any other materials presented to such Purchaser
in connection with the purchase and sale of the Securities constitutes legal, tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in
connection with its purchase of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Legends</U>. Such Purchaser understands that, until such time as the Shares
and/or Warrant Shares may be sold pursuant to Rule 144, any certificates representing the Shares and/or Warrant Shares, whether maintained in a book entry system or otherwise, will bear one or more legends in substantially the following form and
substance: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST
OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS
EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND, IN THE CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, THE HOLDER WILL NOTIFY ANY SUBSEQUENT PURCHASER
OF THE SECURITIES EVIDENCED BY THIS CERTIFICATE FROM IT OF SUCH RESALE RESTRICTIONS.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;ANY TRANSFER OF THE SECURITIES EVIDENCED
BY THIS CERTIFICATE IS SUBJECT TO COMPLIANCE WITH THE TERMS OF A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT, A COPY OF WHICH IS AVAILABLE FROM THE COMPANY.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any stock certificates, whether maintained in a book entry system or otherwise, representing the Shares and/or Warrant Shares may
contain any legend required by the blue sky laws of any state to the extent such laws are applicable to the sale of such Shares and/or Warrant Shares hereunder. The Company shall use its commercially reasonable efforts to help facilitate the removal
of such legend when it is legally permitted to do so under Rule 144, or to facilitate any transfer of the Shares and/or Warrant Shares under Rule 144 that may be requested by Purchasers but shall not be obligated to incur any material costs or
expenses in making such efforts other than as set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall, at its sole expense, upon appropriate notice from any
Purchaser stating that Shares and/or Warrant Shares have been sold pursuant to an effective registration statement, cause its transfer agent to timely prepare and deliver certificates or book-entry shares representing the Shares and/or Warrant
Shares to be delivered to a transferee pursuant to the registration statement, which certificates or book-entry shares shall be free of any restrictive legends and in such denominations and registered in such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
names as such Purchaser may request. Further, the Company shall, at its sole expense, cause its legal counsel or other counsel satisfactory to the transfer agent: (i)&nbsp;while the registration
statement is effective, to issue to the transfer agent a &#147;blanket&#148; legal opinion to allow sales without restriction pursuant to the effective registration statement, and (ii)&nbsp;provide all other opinions as may reasonably be required by
the transfer agent in connection with the removal of legends. A Purchaser may request that the Company remove, and the Company agrees to authorize the removal of, any legend from such Shares and/or Warrant Shares, following the delivery by a
Purchaser to the Company or the Company&#146;s transfer agent of a legended certificate representing such Shares and/or Warrant Shares: (i)&nbsp;following any sale of such Shares and/or Warrant Shares pursuant to Rule 144, (ii) if such Shares and/or
Warrant Shares are eligible for sale under Rule 144(b)(1), or (iii)&nbsp;following the time that the registration statement is declared effective. If a legend removal request is made pursuant to the foregoing, the Company will, no later than two
Business Days following the delivery by a Purchaser (if the request is made on or after five Business Days prior to the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period set forth in <U>Section</U><U></U><U>&nbsp;6.2(b)</U>,
or if prior to such time, no later than five business days) to the Company or the Company&#146;s transfer agent of a legended certificate representing such Shares and/or Warrant Shares (or a request for legend removal, in the case of Shares and/or
Warrant Shares issued in book-entry form), deliver or cause to be delivered to such Purchaser a certificate representing such Shares and/or Warrant Shares that is free from all restrictive legends or an equivalent book-entry position, as requested
by the Purchaser. Certificates for Shares and/or Warrant Shares free from all restrictive legends may be transmitted by the Company&#146;s transfer agent to the Purchasers by crediting the account of the Purchaser&#146;s prime broker with the
Depository Trust Company (&#147;<B><I>DTC</I></B>&#148;) as directed by such Purchaser. If a Purchaser effects a transfer of the Shares and/or Warrant Shares in accordance with this <U>Section</U><U></U><U>&nbsp;5.11</U>, the Company shall permit
the transfer and shall promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Purchaser to effect such transfer.
Each Purchaser hereby agrees that the removal of the restrictive legend pursuant to this <U>Section</U><U></U><U>&nbsp;5.11</U> is predicated upon the Company&#146;s reliance that such Purchaser will sell any such Shares and/or Warrant Shares
pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and such Purchaser will not sell any such Shares and/or Warrant Shares during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period, and such Purchaser shall deliver a certificate reasonably satisfactory to the Company to the foregoing effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Restricted Securities</U>. Such Purchaser understands that the Securities are characterized as &#147;restricted securities&#148; under
the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such Securities may be resold without registration under the
Securities Act only in certain limited circumstances. Accordingly, such Purchaser represents that it is familiar with Rule 144 of the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>No &#147;Bad Actor&#148; Disqualification Events</U>. Neither (i)&nbsp;the Purchaser, (ii)&nbsp;any of its
directors, executive officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing members, nor (iii)&nbsp;any beneficial owner of the Company&#146;s voting equity securities (in
accordance with Rule 506(d) of the Securities Act) held by the Purchaser is subject to any Disqualification Event, except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) under the Securities Act and disclosed
reasonably in advance of the Closing in writing in reasonable detail to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;6 REGISTRATION OF THE SHARES AND COMPLIANCE WITH THE SECURITIES ACT. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Registration Procedures and Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement</U>. The Company shall, on or before January&nbsp;31, 2024 (the &#147;<B><I>Filing Deadline</I></B>&#148;),
prepare and file with the Commission a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or <FONT STYLE="white-space:nowrap">S-3,</FONT> as appropriate (the &#147;<B><I>Registration Statement</I></B>&#148;), relating to and
providing for the resale of the Shares and/or Warrant Shares by the Purchasers on a continuous basis pursuant to Rule 415 under the Securities Act;<I> provided</I>, that the Purchasers have completed a form of questionnaire as may reasonably be
requested by the Company at least 30 days prior to the Filing Deadline and have provided any other information regarding the holder and the distribution of the Securities as the Company may, from time to time, reasonably request for inclusion in a
Registration Statement pursuant to applicable law. Notwithstanding the foregoing, the Company&#146;s obligations under this Section&nbsp;6.1(a) shall terminate at such time as the Shares and/or Warrant Shares become eligible for resale without any
volume limitations or other restrictions pursuant to Rule 144(b)(1)(i) under the Securities Act or any other rule of similar effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<U>Effectiveness Deadline</U>. The Company shall use its commercially reasonable efforts, subject to receipt of necessary information from the Purchasers, to cause the Commission to declare a Registration Statement covering the Shares and/or Warrant
Shares effective as soon as practicable after the date of the filing thereof and in any event within five (5)&nbsp;Business Days after the earlier of (i)&nbsp;the date on which the staff of the Commission (the &#147;<B><I>Staff</I></B>&#148;)
indicates via email or telephone that it will not review or has no further comments on the Registration Statement, or (ii)&nbsp;the filing of the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for fiscal 2023, but
in no event later than April&nbsp;1, 2024 (such date, the &#147;<B><I>Effectiveness Deadline</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall
promptly prepare and file with the Commission such amendments and supplements to the Registration Statement and the prospectus used in connection therewith as may be necessary to keep the Registration Statement effective until the earliest of
(i)&nbsp;the second anniversary of the effective date of the Registration Statement, (ii)&nbsp;such time as all of the Shares and/or Warrant Shares purchased by the Purchasers pursuant to the terms of this Agreement have been sold pursuant to the
Registration Statement, or (iii)&nbsp;such time as the Shares and/or Warrant Shares become eligible for resale by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> without any volume limitations or other restrictions pursuant to Rule
144(b)(1)(i) under the Securities Act or any other rule of similar effect (the &#147;<B><I>Effectiveness Period</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If
either: (a)&nbsp;the Registration Statement is (i)&nbsp;not filed with the Commission on or before the Filing Deadline in violation of <U>Section</U><U></U><U>&nbsp;6.1(a)</U> (a &#147;<B><I>Filing Failure</I></B>&#148;), or (ii)&nbsp;if filed but
not declared effective by the Commission on or before the Effectiveness Deadline (an &#147;<B><I>Effectiveness Failure</I></B>&#148;), or (b)&nbsp;on any day during the Effectiveness Period and after the date on which the Registration Statement is
declared effective, sales of all of the Shares and/or Warrant Shares required to be included on such Registration Statement cannot be made (other than during a Blackout Period) pursuant to such Registration Statement (including, without limitation,
because of a failure to keep such Registration Statement effective, to disclose such information as is necessary for sales to be made pursuant to such Registration Statement or to register a sufficient number of Shares and/or Warrant Shares as
required by this Agreement) (a &#147;<B><I>Maintenance Failure</I></B>&#148;), then, in satisfaction of the damages to any Purchaser by reason of any such delay in or reduction of its ability to sell the Shares and/or Warrant Shares, the Company
shall pay to each such Purchaser then holding Shares and/or Warrant Shares relating to such Registration Statement an amount in cash equal to 1.0% of the Purchase Price for the Shares and/or Warrant Shares then held by such Purchaser on each of the
following dates (as applicable): (x) on every thirtieth (30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day (prorated for periods totaling less than 30 days) following such Filing Failure until such Filing Failure is cured; (y)&nbsp;on
every thirtieth (30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day (prorated for periods totaling less than 30 days) following such Effectiveness Failure until such Effectiveness Failure is cured; and (z)&nbsp;on every thirtieth (30<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) day (prorated for periods totaling less than 30 days) following such Maintenance Failure until such Maintenance Failure is cured. The payments to which a Purchaser shall be entitled pursuant to
this <U>Section</U><U></U><U>&nbsp;6.1(d)</U> are referred to herein as &#147;<B><I>Registration Delay Payments</I></B>&#148;; provided that no Registration Delay Payments shall be required following the termination of the Effectiveness Period, and
provided further that in no event shall the aggregate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Delay Payments accruing under this <U>Section</U><U></U><U>&nbsp;6.1(d)</U> exceed 6% of the Purchase Price for the Securities then held by such Purchaser (i.e., corresponding to a
total delay of six months). In no event shall the Company be obligated to pay any damages pursuant to this <U>Section</U><U></U><U>&nbsp;6.1(d) </U>to more than one Purchaser in respect of the same Shares and/or Warrant Shares for the same period of
time. The Registration Delay Payments shall be paid on the earlier of (I)&nbsp;the last day of the calendar month during which such Registration Delay Payments are incurred and (II)&nbsp;the third
(3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) Business Day after the event or failure giving rise to the Registration Delay Payments is cured. If a Purchaser elects to receive the Registration Delay Payments and such payments are timely
paid, then the Registration Delay Payments described in this <U>Section</U><U></U><U>&nbsp;6.1(d) </U>shall constitute the Purchasers&#146; exclusive monetary remedy for any Filing Failure, Effectiveness Failure or Maintenance Failure. To the extent
that a Purchaser does not elect to receive the Registration Delay Payments or such payments are not timely made by the Company, then the Purchaser may assert any other damages arising from such delays. The Filing Deadline and Effectiveness Deadline
for a Registration Statement shall be extended without default or damages hereunder in the event that the Company&#146;s failure to file or obtain the effectiveness of the Registration Statement on a timely basis results from the failure of a
Purchaser to timely provide the Company with information requested by the Company and necessary to complete the Registration Statement in accordance with the requirements of the Securities Act. For the sake of clarity, at such time as Shares and/or
Warrant Shares become eligible for resale without any volume limitations or other restrictions pursuant to Rule 144(b)(1)(i) under the Securities Act or any other rule of similar effect, a Purchaser shall not be eligible to receive any Registration
Delay Payments with respect to such Shares and/or Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Related Obligations</U>. At such time as the Company is
obligated to file the Registration Statement with the Commission pursuant to Section&nbsp;6.1(a) hereof, the Company will use commercially reasonable efforts to effect the registration of the Shares and/or Warrant Shares in accordance with the
intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The
Company shall submit to the Commission, within three (3)&nbsp;Business Days after the Company learns that no review of the Registration Statement will be made by the Staff or that the Staff has no further comments on the Registration Statement, as
the case may be, a request for acceleration of effectiveness of such Registration Statement to a time and date not later than two (2)&nbsp;Business Days after the submission of such request, subject to the approval of the Staff. The Company shall
keep each Registration Statement effective pursuant to Rule 415 at all times with respect to each Purchaser&#146;s Shares and/or Warrant Shares until the expiration of the Effectiveness Period. The Company shall ensure that each Registration
Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the
statements therein (in the case of prospectuses, in the light of the circumstances in which they were made) not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company shall notify the Purchasers in writing of the happening of any event, as promptly as practicable after
becoming aware of such event, as a result of which the prospectus included in the Registration Statement, as then in effect, includes an untrue statement of a material fact or omission to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any material, nonpublic information), and promptly prepare a supplement or
amendment to such Registration Statement to correct such untrue statement or omission. The Company shall also promptly notify the Purchasers in writing (i)&nbsp;of any request by the Commission for amendments or supplements to the Registration
Statement or related prospectus or related information, and (ii)&nbsp;of the Company&#146;s reasonable determination that a post-effective amendment to the Registration Statement would be appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company shall use commercially reasonable efforts to prevent the
issuance of any stop order or other suspension of effectiveness of the Registration Statement, or the suspension of the qualification of any of the Shares and/or Warrant Shares for sale in any jurisdiction and, if such an order or suspension is
issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify the Purchasers of the issuance of such order and the resolution thereof or its receipt of notice of the initiation or threat of any proceeding
for such purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Neither the Company nor any affiliate thereof shall identify any Purchaser as an underwriter in any
public disclosure or filing with the Commission or any applicable Trading Market without the prior written consent of such Purchaser, and any Purchaser being deemed an underwriter by the Commission shall not relieve the Company of any obligations it
has under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Blackout Period</U>. Notwithstanding the foregoing obligations, the Company may, upon written notice to
the Purchasers, which notice shall not contain any information that is or the Company reasonably believes is material <FONT STYLE="white-space:nowrap">non-public</FONT> information, for a reasonable period of time after effectiveness, not to exceed
30 days (each, a &#147;<B><I>Blackout Period</I></B>&#148;), delay the filing of an amendment to a Registration Statement or suspend the effectiveness or use of any Registration Statement, in the event that (A)&nbsp;the Company is engaged in any
activity or transaction or preparations or negotiations for any activity or transaction that the Company desires to keep confidential for business reasons, if the Company determines in good faith that the public disclosure requirements imposed on
the Company under the Securities Act in connection with the Registration Statement would require at that time disclosure of such activity, transaction, preparations or negotiations and such disclosure could result in material harm to the Company or
its business transactions or activities, (B)&nbsp;the Company does not yet have appropriate financial statements of any acquired or to be acquired entities necessary for filing, or (C)&nbsp;any other event occurs that makes any statement of a
material fact made in such Registration Statement, including any document incorporated by reference therein, untrue or that requires the making of any additions or changes in the Registration Statement in order to make the statements therein not
misleading; provided, however, that any Blackout Period shall terminate upon the earlier of (i)&nbsp;the expiration of such <FONT STYLE="white-space:nowrap">30-day</FONT> period or (ii)&nbsp;the completion, resolution or public announcement of the
relevant transaction or event. If the Company suspends the effectiveness of a Registration Statement pursuant to this <U>Section</U><U></U><U>&nbsp;6.1(f)</U>, the Company shall (x)&nbsp;as promptly as reasonably practicable following the
termination of the circumstance which entitled the Company to do so, take such actions as may be necessary to reinstate the effectiveness of such Registration Statement and give written notice to the Purchasers authorizing the Purchasers to resume
offerings and sales pursuant to such Registration Statement, and (y)&nbsp;cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of any Purchaser in accordance with the terms of this Agreement in connection with any
sale of Shares and/or Warrant Shares with respect to which a Purchaser has entered into a contract for sale, and delivered a copy of the prospectus included as part of the applicable Registration Statement (unless an exemption from such prospectus
delivery requirement exists), prior to the Purchaser&#146;s receipt of the notice of a Blackout Period and for which the Purchaser has not yet settled. If as a result thereof the prospectus included in such Registration Statement has been amended or
supplemented to comply with the requirements of the Securities Act, the Company shall enclose such revised prospectus with the notice to Purchaser given pursuant to this <U>Section</U><U></U><U>&nbsp;6</U>. The Company shall be entitled to exercise
its rights under this <U>Section</U><U></U><U>&nbsp;6.1(f)</U> not more than once in any six (6)&nbsp;month period; provided, however, that the aggregate number of days of all Blackout Periods hereunder shall not exceed 60 days in any twelve
(12)&nbsp;month period. After the expiration of any Blackout Period and without further request from the Purchaser, the Company shall effect the filing (or if required amendment or supplement) of the Registration Statement, or the filing of other
documents, as necessary to allow the Purchaser to resell the Shares and/or Warrant Shares as set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Registration Expenses</U>. The Company shall bear all expenses in connection with the
procedures in paragraphs (a)&nbsp;through (d) of this <U>Section</U><U></U><U>&nbsp;6.1</U> and the registration of the Shares and/or Warrant Shares pursuant to the Registration Statement, other than fees and expenses, if any, of counsel or other
advisers to the Purchasers or underwriting discounts, brokerage fees and commissions incurred by the Purchaser, if any in connection with the offering of the Shares and/or Warrant Shares pursuant to the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Timely Filing</U>. In order to enable the Purchasers to sell the Shares and/or Warrant Shares under Rule 144 to the Securities Act, the
Company shall use its commercially reasonable efforts during the Effectiveness Period to comply with the requirements of Rule 144, including without limitation, use its commercially reasonable efforts to comply with the requirements of Rule
144(c)(1) with respect to public information about the Company. During the Effectiveness Period, the Company covenants to timely file all reports required to be filed by the Company under the Exchange Act even if the Company is not then subject to
the reporting requirements of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Company shall provide the Purchasers an opportunity to review and comment on all
disclosures regarding the Purchasers and any plan of distribution proposed by them in connection with the preparation of any Registration Statement. Notwithstanding anything to the contrary contained herein, in no event shall the Company be
permitted to name any Purchaser or Affiliate of a Purchaser as an &#147;underwriter&#148; without the prior written consent of such Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Restrictions on Transfer</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Purchaser agrees that it will not effect any disposition of the Shares and/or Warrant Shares that would constitute a sale within the
meaning of the Securities Act or pursuant to any applicable state securities laws, unless and until (1)&nbsp;there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in
accordance with such registration statement or (2)&nbsp;such disposition is otherwise permitted by law, including pursuant to the procedures set forth in Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary in this Agreement, during the period beginning on the Closing Date and ending on the date that is
the earlier of (i)&nbsp;the Company&#146;s public release of the initial data readout of the Phase 1b clinical trial of <FONT STYLE="white-space:nowrap">ORIC-114</FONT> following the date hereof and (ii)&nbsp;December&nbsp;31, 2023 (the &#147;<B><I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;), each<B> </B>Purchaser shall not, directly or indirectly, sell, transfer, pledge, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, transfer the economic risk of ownership of, or otherwise dispose of any of the Securities except: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) in
response to a bona fide public tender offer or exchange offer subject to Regulation 14D or Rule <FONT STYLE="white-space:nowrap">13e-3</FONT> of the rules promulgated under the Exchange Act by the Commission, for cash or other consideration which is
made by or on behalf of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) in connection with a bona fide third-party tender offer, merger, consolidation or other
similar transaction, approved by the board of directors of the Company, made to all holders of Common Stock involving a change of control of the Company, provided that, in the event that such tender offer, merger, consolidation or other similar
transaction is not completed, any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock held by the Purchaser shall remain subject to the restrictions on transfer set forth herein; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) to an Affiliate of Purchaser in one or more transactions, so long as prior to or concurrent with any such transfer such Affiliate agrees
in writing to be bound by the terms of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Indemnification</U>. For the purpose of this <U>Section</U><U></U><U>&nbsp;6.3</U>:
(i) the term &#147;<B><I>Purchaser/Affiliate</I></B>&#148; shall mean any Affiliate of the Purchaser; and (ii)&nbsp;the term &#147;<B><I>Registration Statement</I></B>&#148; shall include any preliminary prospectus, final prospectus (the
&#147;<B><I>Prospectus</I></B>&#148;), free writing prospectus, exhibit, supplement or amendment included in or relating to, and any document incorporated by reference in, the Registration Statement referred to in
<U>Section</U><U></U><U>&nbsp;6.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to indemnify and hold harmless the Purchasers and each Purchaser/Affiliate,
against any losses, claims, damages, liabilities or expenses, joint or several, that such Purchaser or Purchaser/Affiliate incurs, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common
law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated
below)&nbsp;(i) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, including the Prospectus, financial statements and schedules, and all other documents filed
as a part thereof, as amended at the time of effectiveness of the Registration Statement, including any information deemed to be a part thereof as of the time of effectiveness pursuant to paragraph (b)&nbsp;of Rule 430A, or pursuant to Rules 430B,
430C or 434, of the Rules and Regulations, or the Prospectus, in the form first filed with the Commission pursuant to Rule 424(b) of the Regulations, or filed as part of the Registration Statement at the time of effectiveness if no Rule 424(b)
filing is required or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state in any of them a material fact required to be stated therein or necessary to make the statements in the
Registration Statement or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in light of the circumstances under which they were made or (ii)&nbsp;arise out of or are based
in whole or in part on any inaccuracy in the representations or warranties of the Company contained in this Agreement, breach of any covenant of the Company contained in this Agreement or any failure of the Company to perform its other obligations
hereunder or under law, and will promptly reimburse each Purchaser and each Purchaser/Affiliate for any legal and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses as such expenses are
reasonably incurred and documented by such Purchaser or such Purchaser/Affiliate in connection with investigating, defending or preparing to defend, settling, compromising or paying any such loss, claim, damage, liability, expense or action;
provided, however, that the Company will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the written consent of the Company, which consent shall not be
unreasonably withheld or delayed, and the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon (i)&nbsp;the gross negligence or willful misconduct of such
Purchaser or any Purchaser/Affiliate, or (ii)&nbsp;an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Prospectus or any amendment or supplement thereto in reliance upon and in
conformity with written information furnished to the Company by or on behalf of the Purchaser or any Purchaser/Affiliate expressly for use therein, or (iii)&nbsp;the inaccuracy of any representation or warranty made by such Purchaser herein or
(iv)&nbsp;any statement or omission in any Prospectus that is corrected in any subsequent Prospectus that was delivered to the Purchaser prior to the pertinent sale or sales by the Purchaser. Any such indemnified Purchaser shall return all payments
made hereunder if it is determined, by a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment by a court or arbitral tribunal, that the losses for which such payments were made resulted from such indemnified Purchaser&#146;s or any
Purchaser/Affiliate&#146;s gross negligence or willful misconduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Purchaser will severally, but not jointly, indemnify and hold harmless the Company,
each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, against any
losses, claims, damages, liabilities or expenses that the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person incurs, under the Securities Act, the Exchange Act, or any other federal or
state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, but only if such settlement is effected with the written consent of such Purchaser) insofar as such losses, claims, damages, liabilities or
expenses (or actions in respect thereof as contemplated below) arise out of or are based upon (i)&nbsp;any failure to comply with the covenants and agreements contained in <U>Section</U><U></U><U>&nbsp;6.2</U> hereof respecting the sale of the
Shares and/or Warrant Shares or (ii)&nbsp;the inaccuracy of any representation or warranty made by such Purchaser herein or (iii)&nbsp;any untrue or alleged untrue statement of any material fact contained in the Registration Statement, the
Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements in the Registration Statement
or any amendment or supplement thereto not misleading or in the Prospectus or any amendment or supplement thereto not misleading in the light of the circumstances under which they were made, in each case to the extent, but only to the extent, that
such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished
to the Company by or on behalf of such Purchaser or any Purchaser/Affiliate expressly for use therein; and will reimburse the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person for any
legal and other expense reasonably incurred by the Company, each of its directors, each of its officers who signed the Registration Statement or controlling person in connection with investigating, defending, settling, compromising or paying any
such loss, claim, damage, liability, expense or action; provided, however, that (i)&nbsp;each Purchaser&#146;s aggregate liability under this <U>Section</U><U></U><U>&nbsp;6</U> shall not exceed the amount of proceeds received by such Purchaser on
the sale of the Shares and/or Warrant Shares pursuant to the Registration Statement and (ii)&nbsp;the Purchaser will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected
without the written consent of such Purchaser which consent shall not be unreasonably withheld or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by
an indemnified party under this <U>Section</U><U></U><U>&nbsp;6.3</U> of notice of the threat or commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this
<U>Section</U><U></U><U>&nbsp;6.3</U> promptly notify the indemnifying party in writing thereof, but the omission to notify the indemnifying party will not relieve it from any liability that it may have to any indemnified party for contribution or
otherwise under the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;6.3</U> to the extent it is not prejudiced as a result of such failure. In case any such action is brought against any indemnified party and such indemnified
party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it may wish, jointly with all other indemnifying parties similarly notified, to assume the
defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party, and the indemnifying party and the indemnified party shall have reasonably
concluded, based on an opinion of counsel reasonably satisfactory to the indemnifying party, that there may be a conflict of interest between the positions of the indemnifying party and the indemnified party in conducting the defense of any such
action or that there may be legal defenses available to it and/or other indemnified parties that are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate
counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of its election to assume
the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this <U>Section</U><U></U><U>&nbsp;6.3</U> for any legal or other expenses subsequently
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed such counsel in connection with the assumption of legal
defenses in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel, reasonably satisfactory to such indemnifying party,
representing all of the indemnified parties who are parties to such action) or (ii)&nbsp;the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable
time after notice of commencement of action, in each of which cases the reasonable fees and expenses of counsel shall be at the expense of the indemnifying party. In no event shall any indemnifying party be liable in respect of any amounts paid in
settlement of any action unless the indemnifying party shall have approved in writing the terms of such settlement; provided that such consent shall not be unreasonably withheld. No indemnifying party shall, without the prior written consent of the
indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnification could have been sought hereunder by such indemnified party, unless such
settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;6.3</U> is required by its terms but is for any reason held to
be unavailable to or otherwise insufficient to hold harmless an indemnified party under paragraphs (a), (b) or (c)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.3</U> in respect to any losses, claims, damages, liabilities or expenses referred to
herein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein (i)&nbsp;in such proportion as is
appropriate to reflect the relative benefits received by the Company and the Purchaser from the private placement of Securities hereunder or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but the relative fault of the Company and the Purchaser in connection with the statements or omissions or inaccuracies in the representations
and warranties in this Agreement and/or the Registration Statement that resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company on the
one hand and each Purchaser on the other shall be deemed to be in the same proportion as the amount paid by such Purchaser to the Company pursuant to this Agreement for the Securities purchased by such Purchaser that were sold pursuant to the
Registration Statement bears to the difference (the &#147;<B><I>Difference</I></B>&#148;) between the amount such Purchaser paid for the Securities that were sold pursuant to the Registration Statement and the amount received by such Purchaser from
such sale. The relative fault of the Company on the one hand and each Purchaser on the other shall be determined by reference to, among other things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to
state a material fact or the inaccurate or the alleged inaccurate representation and/or warranty relates to information supplied by the Company or by such Purchaser and the parties&#146; relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set
forth in paragraph (c)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.3</U>, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in paragraph
(c)&nbsp;of this <U>Section</U><U></U><U>&nbsp;6.3</U> with respect to the notice of the threat or commencement of any threat or action shall apply if a claim for contribution is to be made under this paragraph (d); provided, however, that no
additional notice shall be required with respect to any threat or action for which notice has been given under paragraph (c)&nbsp;for purposes of indemnification. The Company and the Purchaser agree that it would not be just and equitable if
contribution pursuant to this <U>Section</U><U></U><U>&nbsp;6.3</U> were determined solely by pro rata allocation (even if the Purchaser were treated as one entity for such purpose) or by any other method of allocation which does not take account of
the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;6.3</U>, no Purchaser shall be required to contribute any amount in excess of the amount by which the Difference exceeds
the amount of any damages that such Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Purchasers&#146; obligations to contribute pursuant to this
<U>Section</U><U></U><U>&nbsp;6.3</U> are several and not joint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;7 NO BROKER&#146;S FEES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Company and the Purchasers hereby represents that no broker, investment banker, financial advisor or other individual, corporation,
general or limited partnership, limited liability company, firm, joint venture, association, enterprise, joint securities company, trust, unincorporated organization or other entity is entitled to any broker&#146;s, finder&#146;s, financial
advisor&#146;s financial advisor&#146;s or other similar fee or commission in connection with the transactions contemplated by this Agreement. Each party hereto further agrees to indemnify each other party for any claims, losses or expenses incurred
by such other party as a result of the representation in this <U>Section</U><U></U><U>&nbsp;7</U> being untrue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8 COVENANTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Form D; Blue Sky Filings</U>. The Company agrees to file a Form D with respect to the Securities as required under Regulation D of the
Securities Act. The Company will take such action as the Company shall reasonably determine is necessary in order to obtain an exemption from, or to qualify the Securities for, sale to the Purchasers at each of the Closings respectively pursuant to
this Agreement under applicable securities of &#147;Blue Sky&#148; laws of the states of the United States and shall provide evidence of such actions promptly upon the written request of the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U><FONT STYLE="white-space:nowrap">Lock-up</FONT></U>. The Company covenants and agrees that it shall not waive the terms of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> set forth in Section&nbsp;6.2(b) unless such waiver applies to all Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Listing
of Common Stock</U>. The Company shall promptly secure the listing of the Shares and/or Warrant Shares upon each national securities exchange and automated quotation system that requires an application by the Company for listing, if any, upon which
shares of Common Stock are then listed (subject to official notice of issuance). The Company shall pay all fees and expenses in connection with satisfying its obligations under this <U>Section</U><U></U><U>&nbsp;8.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U><FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</U>. The Company has not provided the Purchasers with any information
that will constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information upon the expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 NOTICES. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices,
requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed facsimile or electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage
prepaid, and shall be deemed given when so sent in the case of facsimile or electronic mail transmission, or when so received in the case of mail or courier, and addressed as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if to the Company, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">240
E. Grand Ave., 2nd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">South San Francisco, California 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: President and Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: jacob.chacko@oricpharma.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Legal Department </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:
legal@oricpharma.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">650 Page Mill Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Palo Alto,
CA 94304 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Jennifer Knapp </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: jknapp@wsgr.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other Person
at such other place as the Company shall designate to the Purchasers in writing; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if to the Purchasers, to the address set forth
on <U>Schedule A</U> or to such other Person at such other place as the Purchasers shall designate to the Company in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;10
MISCELLANEOUS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Waivers and Amendments</U>. Neither this Agreement nor any provision hereof may be changed, waived, discharged,
terminated, modified or amended except upon the written consent of the Company and the Purchasers holding at least a majority of the Securities then held by Purchasers; provided that if any amendment or waiver disproportionately and adversely
affects a Purchaser (or group of Purchasers) in any material respect, the consent of such disproportionately affected Purchaser (or group of Purchasers) shall also be required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>Headings; Interpretation</U>. The headings of the various sections of this Agreement have been inserted for convenience of reference
only and shall not be deemed to be part of this Agreement. The terms &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148; and derivative or similar words refer to this Agreement as a whole and not to any particular provision of this Agreement.
Except when used together with the word &#147;either&#148; or otherwise for the purpose of identifying mutually exclusive alternatives, the term &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or.&#148; All references in
this Agreement to &#147;dollars&#148; or &#147;$&#148; shall mean United States dollars. Except where the context otherwise requires, wherever used the singular shall include the plural, the plural the singular, the use of any gender shall be
applicable to all genders. The term &#147;including&#148; or &#147;includes&#148; means &#147;including without limitation&#148; or &#147;includes without limitation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Severability</U>. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 <U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Shares and <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. The agreements and covenants contained herein shall survive for the applicable statute of limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5 <U>Governing Law; Jurisdiction</U>. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the
State of New York, without regard to its or any other jurisdiction&#146;s choice of law rules. Any and all disputes arising out of, concerning, or related to this Agreement, or to the interpretation, performance, breach or termination thereof shall
be referred to and resolved by the federal courts located in New York, New York. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE
SECURITIES OR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT
AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY
DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY
KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6 <U>Counterparts</U>. This
Agreement may be executed in counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each
party hereto and delivered to the other party. Signatures to this Agreement transmitted by facsimile, by email in &#147;portable document format&#148; (&#147;.pdf&#148;), or by any other electronic means intended to preserve the original graphic and
pictorial appearance of this Agreement shall have the same effect as physical delivery of the paper document bearing original signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7 <U>Successors and Assigns</U>. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be
binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. None of the Purchasers may assign this Agreement or any rights or obligations hereunder, in whole or in part, without the prior written consent of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.8 <U>No Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in <U>Section</U><U></U><U>&nbsp;6.3</U> and this <U>Section</U><U></U><U>&nbsp;10.8</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.9 <U>Entire Agreement</U>. This Agreement and the other documents and instruments delivered pursuant hereto or thereto, including the
exhibits and schedules hereto or thereto, constitute the full and entire understanding and agreement between the parties hereto with regard to the subjects hereof and thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.10 <U>Independent Nature of Purchasers&#146; Obligations and Rights</U>. The obligations of each Purchaser under this Agreement are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein and no action taken by any
Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group, or
are deemed affiliates (as such term is defined under the Exchange Act) with respect to such obligations or the transactions contemplated by this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including
without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser acknowledges that it is not relying upon any
person, firm, or corporation, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. Each Purchaser agrees that no Purchaser nor the respective controlling persons, officers, directors,
partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.11 <U>Payment of Fees and Expenses</U>. Except as otherwise provided herein or in the
other documents or instruments contemplated hereby, each of the Company and the Purchasers shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby; provided that, at
the Closing, the Company shall pay the documented and reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal fees and expenses of Nextech Invest Ltd. and affiliated entities (as lead investor
hereunder), not to exceed $75,000 in the aggregate. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney&#146;s fees, costs and necessary
disbursements in addition to any other relief to which such party may be entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.12 <U>Further Actions</U>. Each party hereto agrees
to execute, acknowledge, and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.13 <U>Form <FONT STYLE="white-space:nowrap">8-K</FONT></U>. As soon as practicable, and in any event by the fourth (4th) Business Day
following the Effective Date, the Company shall file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the Commission describing the terms of the transactions contemplated by this Agreement and attaching this Agreement as an
exhibit to such filing (the &#147;<B><I>Form <FONT STYLE="white-space:nowrap">8-K</FONT></I></B>&#148;); provided, however that the Purchasers shall be given an opportunity to review and comment on the disclosure contained in such Current Report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> prior to filing. Except for the Form <FONT STYLE="white-space:nowrap">8-K</FONT> contemplated by this <U>Section</U><U></U><U>&nbsp;10.13</U>, all public announcements regarding this Agreement shall
be issued only in accordance with <U>Section</U><U></U><U>&nbsp;10.14</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.14 <U>Public Announcement</U>. No press release or, except
to the extent required under applicable law, other public announcement shall be made, directly or indirectly, by either party hereto concerning the execution of this Agreement, the terms and conditions hereof or the consummation of the transactions
contemplated hereby, in each case without the prior written consent of the other party hereto, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, the Company may issue a press release in
connection with the execution of this Agreement to announce the execution of this Agreement, the terms and conditions hereof and/or the consummation of the transactions contemplated hereby without the consent of any other party hereto, provided that
such press release will not include the name of a Purchaser without such Purchaser&#146;s consent. The Company shall not include the name of any of the Purchasers in the public disclosure or any other public announcement or publication without the
prior written consent of such Purchaser, except as required by law, rule, regulation or applicable SEC guidance, provided however that the parties agree and understand that the Purchasers shall be listed in the selling stockholder section of the
Registration Statement(s) filed in connection with the Securities issued to the Purchasers pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.15 <U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is
also offered to all of the parties to such Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser and shall not in any way be construed
as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Common Stock or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ORIC PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Jacob M. Chacko, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jacob M. Chacko, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Securities Purchase Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NEXTECH CROSSOVER I SCSP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Nextech Crossover I GP S.&aacute;.r.l., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ian Charoub</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ian Charoub</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NEXTECH CROSSOVER I SCSP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Nextech Crossover I GP S.&aacute;.r.l., its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Costas Constantinides</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Costas Constantinides </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Securities Purchase Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ECOR1 CAPITAL FUND, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: EcoR1 Capital, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Oleg Nodelman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Oleg Nodelman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ECOR1 CAPITAL FUND QUALIFIED, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: EcoR1 Capital, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Oleg Nodelman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Oleg Nodelman </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Securities Purchase Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: VHCP Management EG, LLC, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sherman Souther</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sherman Souther </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: VHCP Management III, LLC, its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: VR Adviser, LLC, its manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Sherman Souther</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sherman Souther</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VHCP <FONT STYLE="white-space:nowrap">CO-INVESTMENT</FONT> HOLDINGS III, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: VHCP Management III, LLC, its manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: VR Adviser, LLC, its manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Sherman Souther</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sherman Souther</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Securities Purchase Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRAZIER LIFE SCIENCES X, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: FHMLS X, L.P., its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: FHMLS X, L.L.C., its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Patrick Heron</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Patrick Heron </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRAZIER LIFE SCIENCES XI, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: FHMLS XI, L.P., its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: FHMLS XI, L.L.C., its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Patrick Heron</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Patrick Heron</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: FHMLSP, L.P., its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: FHMLSP, L.L.C., its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Albert Cha</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Albert Cha</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director </P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: FHMLSP Overage, L.P., its general partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: FHMLSP Overage, L.L.C., its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Albert Cha</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Albert Cha</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Securities Purchase Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PURCHASERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BOXER CAPITAL, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Aaron Davis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aaron Davis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MVA INVESTORS, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Aaron Davis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Aaron Davis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Securities Purchase Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Filed separately as Exhibit&nbsp;4.1] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF D&amp;O <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORIC Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[&#149;], 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">240 E. Grand Ave., 2nd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, California
94080 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <U>ORIC Pharmaceuticals, Inc. - <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that ORIC Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) is party to that certain Securities Purchase Agreement dated on or about the date hereof (the &#147;<B><I>Purchase Agreement</I></B>&#148;) providing for the sale
and issuance of the Company&#146;s Securities. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the entry into the Purchase Agreement, and of other good and valuable consideration the receipt and sufficiency of which
is hereby acknowledged, the undersigned agrees that, during the period beginning on the date hereof and continuing until the termination of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period under the Purchase Agreement (the &#147;<B><I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#148;), the undersigned shall not, without the prior written consent of the Company, subject to the exceptions set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of the Company&#146;s Common Stock or any securities convertible into or exercisable or exchangeable for the Company&#146;s Common Stock, whether
now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares</I></B>&#148;), or publicly
disclose the intention to make any offer, sale, pledge or disposition of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Shares, whether any such transaction described in clause (1)&nbsp;above or this clause (2)&nbsp;is to be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Shares or such other
securities, in cash or otherwise, in each case other than: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) transfers as a bona fide gift or gifts, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) transfers or dispositions to any trust for the direct or indirect benefit of the undersigned, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) distributions by a trust to its beneficiaries, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) transfers or dispositions to any corporation, partnership, limited liability company or other entity, all of the beneficial
ownership interests of which are held by undersigned, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) transfers or dispositions by will, other testamentary document or
intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of undersigned, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) transfers to partners, members or stockholders of the undersigned, or to another partnership, limited liability company,
corporation or other business entity that controls, is controlled by or is under common control with the undersigned; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(G)
transfers pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction, approved by the board of directors of the Company, made to all holders of Common Stock involving a change of control of the Company,
provided that, in the event that such tender offer, merger, consolidation or other similar transaction is not completed, any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock held by the
undersigned shall remain subject to the restrictions on transfer set forth herein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(H) the receipt by the undersigned from
the Company of shares of Common Stock upon the exercise of options or the settlement of restricted stock units; provided that the Common Stock received as a result of such exercise, vesting or settlement shall remain subject to the restrictions on
transfer set forth in this agreement and any filing under Section&nbsp;16 of the Exchange Act made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that the filing relates to the
circumstances described in this clause; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(I) transfers to the Company for the purposes of exercising (including for the
payment of tax withholdings or remittance payments due as a result of such exercise) on a &#147;net exercise&#148; or &#147;cashless&#148; basis options or other equity awards or (ii)&nbsp;transfers for the payment of tax withholdings or remittance
payments due as a result of the vesting or settlement of such restricted stock units; provided that the Common Stock issued shall remain subject to the restrictions on transfer set forth in this agreement and any filing under Section&nbsp;16 of the
Exchange Act made during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(J) transfers to the Company pursuant to any contractual arrangement that provides for the repurchase by the Company or
forfeiture of the undersigned&#146;s Common Stock in connection with the termination of the undersigned&#146;s service to the Company; provided that if the undersigned is required to file a report under Section&nbsp;16 of the Exchange Act reporting
a reduction in beneficial ownership of shares of Common Stock during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to the termination of the
undersigned&#146;s employment or other services; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(K) transfers under a <FONT STYLE="white-space:nowrap">10b5-1</FONT>
Trading Plan (as defined below) that is existing on the date hereof; provided that if the undersigned is required to file a report under Section&nbsp;16 of the Exchange Act reporting such transfer during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to a transfer in accordance with a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that (x)&nbsp;in the case of any transfer or distribution pursuant to clauses (A) - (F), each transferee, donee or
distributee shall execute and deliver to the Company a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this letter agreement. For purposes of this agreement, &#147;immediate family&#148; shall mean any relationship by blood,
marriage or adoption, not more remote than first cousin. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the undersigned shall be released from all obligations
under this letter agreement if the Purchase Agreement shall terminate or be terminated prior to the Closing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d462067dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g462067dsp14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORIC Pharmaceuticals Announces $85 Million Private Placement Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;26, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Financing led by Nextech
and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Pro
forma cash and investments expected to fund current operating plan into late 2025 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO,
June</B><B></B><B>&nbsp;26, 2023 (GLOBE NEWSWIRE) &#150;</B> ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today has agreed to sell
approximately 12.1&nbsp;million shares of its common stock (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at
a price per share of $7.00, representing a premium of approximately 15% to ORIC&#146;s <FONT STYLE="white-space:nowrap">30-day</FONT> volume-weighted average price and approximately 8% to the closing price on June&nbsp;23, 2023. The <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable, and will remain exercisable until exercised in full. The financing is expected to close on
June&nbsp;27, 2023, subject to customary closing conditions. ORIC anticipates the gross proceeds from the private placement to be approximately $85&nbsp;million, before deducting any offering related expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing includes participation from new and existing institutional investors and is being led by
Nextech<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> with participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital. Participating investors entered into confidentiality agreements and
executed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with ORIC to restrict their ability to sell ORIC shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As the competitive
profiles of multiple of our clinical programs begin to emerge with respect to internally generated data and competitor updates, the added financial firepower provided by this blue-chip syndicate of investors, both new and existing and with whom
we&#146;ve had longstanding relationships, allows us to aggressively advance our pipeline for the benefit of patients,&#148; said Jacob M. Chacko, MD, chief executive officer. &#147;The extended cash runway positions us well, and we look forward to
presenting initial clinical data from our three clinical programs over the coming quarters while continuing to advance our mission of overcoming resistance in cancer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are thrilled to become long-term partners to ORIC&#146;s ambitious management team at this critical inflection point as they look to accelerate the
development of their pipeline of differentiated programs with clinical profiles that are now emerging,&#148; said Kanishka Pothula, Partner at Nextech. &#147;We believe that this team&#146;s broad capabilities spanning discovery research,
translational expertise, thoughtfully-designed clinical trials, and strong business development networks, combined with their data driven decision-making and financial discipline, uniquely position ORIC to achieve meaningful impact on patients&#146;
lives.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC anticipates the following upcoming milestones: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ORIC-114:</FONT> Report initial safety, PK/PD, and preliminary antitumor
activity data from ongoing single agent Phase 1b study in patients with EGFR/HER2-mutated cancers in the second half of 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ORIC-533:</FONT> Report initial safety, PK/PD, and preliminary antitumor
activity data from ongoing single agent Phase 1b study in patients with multiple myeloma in the second half of 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ORIC-944:</FONT> Report initial safety, PK/PD, and preliminary antitumor
activity data from ongoing single agent Phase 1b study in patients with prostate cancer in the first quarter of 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC intends to
use the net proceeds from the proposed financing to fund research and development of its clinical-stage product candidates and research programs and for working capital and general corporate purposes. The proceeds from this financing, combined with
current cash, cash equivalents and marketable securities, is expected to be sufficient to fund the current operating plan into late 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities
described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption
from the registration </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">requirements of the Securities Act. ORIC has agreed to file a registration statement with the U.S. Securities and Exchange
Commission (the &#147;SEC&#148;) registering the resale of the shares of common stock and the shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in this private placement. Any
offering of the securities under the resale registration statement will only be made by means of a prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ORIC Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients&#146; lives by<I> Overcoming</I><I></I><I>
Resistance</I><I></I><I> In</I><I></I><I> Cancer.</I><I></I> ORIC&#146;s clinical stage product candidates include <FONT STYLE="white-space:nowrap">(1)&nbsp;ORIC-533,</FONT> an orally bioavailable small molecule inhibitor of CD73, a key node in the
adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, <FONT STYLE="white-space:nowrap">(2)&nbsp;ORIC-114,</FONT> a brain penetrant inhibitor
designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and <FONT STYLE="white-space:nowrap">(3)&nbsp;ORIC-944,</FONT> an allosteric inhibitor
of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms.
ORIC has offices in South San Francisco and San Diego, California. For more information, please go to&nbsp;<U>www.oricpharma.com</U>, and follow us on&nbsp;<U>Twitter</U>&nbsp;or&nbsp;<U>LinkedIn</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements as that term is defined in Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the
Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the timing and expectation of the closing of the private
placement; the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; statements regarding ORIC&#146;s development plans and timelines; the potential advantages of ORIC&#146;s
product candidates and programs; plans underlying ORIC&#146;s clinical trials and development; the expected timing of reporting initial data from the <FONT STYLE="white-space:nowrap">ORIC-533,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114</FONT>
and <FONT STYLE="white-space:nowrap">ORIC-944</FONT> clinical trials; anticipated upcoming milestones; plans underlying any of ORIC&#146;s other programs; the period over which ORIC estimates the proceeds from the private placement, combined with
its existing cash, cash equivalents and investments, will be sufficient to fund its current operating plan; and statements by the company&#146;s chief executive officer and Mr.&nbsp;Pothula. Words such as &#147;believes,&#148;
&#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;will,&#148; &#147;goal,&#148; &#147;potential&#148; and similar expressions are intended to identify forward-looking statements. The forward-looking
statements contained herein are based upon ORIC&#146;s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking
statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an
early clinical stage company; ORIC&#146;s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC&#146;s plans to develop and
commercialize its product candidates; the potential for clinical trials of <FONT STYLE="white-space:nowrap">ORIC-533,</FONT> <FONT STYLE="white-space:nowrap">ORIC-114,</FONT> <FONT STYLE="white-space:nowrap">ORIC-944</FONT> or any other product
candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on ORIC&#146;s operations, including clinical trials; the risk of the
occurrence of any event, change or other circumstance that could give rise to the termination of ORIC&#146;s license and collaboration agreements; ORIC&#146;s ability to raise any additional funding it will need to continue to pursue its business
and product development plans; regulatory developments in the United States and foreign countries; ORIC&#146;s reliance on third parties, including contract manufacturers and contract research organizations; ORIC&#146;s ability to obtain and
maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information
regarding the foregoing and additional risks may be found in the section entitled &#147;Risk Factors&#148; in ORIC&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC on May&nbsp;8, 2023, and ORIC&#146;s
future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements, except as required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dominic Piscitelli, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>dominic.piscitelli@oricpharma.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>info@oricpharma.com
</U></P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nextech Invest Ltd, on behalf of one or more funds managed by it. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>oric-20230624.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/27/2023 8:00:59 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:oric="http://www.oricpharma.com/20230624"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.oricpharma.com/20230624"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20230624_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oric-20230624_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>oric-20230624_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/27/2023 8:00:59 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>oric-20230624_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/27/2023 8:00:59 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="oric-20230624.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g462067dsp14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g462067dsp14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-(259!32!4
M25=!4DD   60 P "    %   $*:0!  "    %   $+J2D0 "     S$V  "2
MD@ "     S$V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139651555399024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001796280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 24,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORIC Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1787157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">240 E. Grand Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">388-5600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORIC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d462067d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="oric-20230624.xsd" xlink:type="simple"/>
    <context id="duration_2023-06-24_to_2023-06-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <startDate>2023-06-24</startDate>
            <endDate>2023-06-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-06-24_to_2023-06-24">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-06-24_to_2023-06-24"
      id="Hidden_dei_EntityCentralIndexKey">0001796280</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-06-24_to_2023-06-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-06-24_to_2023-06-24">2023-06-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-06-24_to_2023-06-24">ORIC Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-06-24_to_2023-06-24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-06-24_to_2023-06-24">001-39269</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-06-24_to_2023-06-24">47-1787157</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-06-24_to_2023-06-24">240 E. Grand Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-06-24_to_2023-06-24">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-06-24_to_2023-06-24">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-06-24_to_2023-06-24">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-06-24_to_2023-06-24">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-06-24_to_2023-06-24">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-06-24_to_2023-06-24">388-5600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-06-24_to_2023-06-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-06-24_to_2023-06-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-06-24_to_2023-06-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-06-24_to_2023-06-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-06-24_to_2023-06-24">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-06-24_to_2023-06-24">ORIC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-06-24_to_2023-06-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-06-24_to_2023-06-24">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-06-24_to_2023-06-24">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *\PVU8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "O,-M6*(VL:>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O33%B:'KBV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN
M=W"-#E+W$9]C'S"2Q70SNLXGJ<.:'8F"!$CZB$ZE,B=\;N[[Z!3E9SQ 4/I#
M'1 $YRMP2,HH4C !B[ 06=L8+75$17T\XXU>\.$S=C/,:, .'7I*4)45L'::
M&$YCU\ 5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.=1S+N]0P=O3X\N\;F%]
M(N4UYE_)2CH%7+/+Y-?Z8;/;LE9P41=\58B[7<4EOY7B_GUR_>%W%7:]L7O[
MCXTO@FT#O^ZB_0)02P,$%     @ KS#;5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "O,-M6A;0U8(@$  #5$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V8;W/B-A#&OXK&O>FT,PFVQ?\4F"$DN:9WE]! >S/M](6P!6AB6ZXD _GV
M7=G$YJYFS1NPP7K\T^[J6=FCO52O>LNY(8<X2O38V1J3WKBN#K8\9KHE4Y[
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( *\PVU8D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "O,-M699!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ KS#;5BB-K&GO    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ KS#;5IE<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "O,-M6A;0U8(@$  #5$0  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ KS#;5I^@&_"Q
M @  X@P   T              ( !S P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " "O,-M6EXJ[',     3 @  "P              @ &H#P  7W)E;',O
M+G)E;'-02P$"% ,4    " "O,-M6'#AEZC\!   \ @  #P
M@ &1$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ KS#;5B0>FZ*M
M^ $  !H              ( !_1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ KS#;5F60>9(9 0  SP,  !,              ( !
MXA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  +!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d462067d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d462067d8k.htm">d462067d8k.htm</File>
    <File>d462067dex101.htm</File>
    <File>d462067dex41.htm</File>
    <File>d462067dex991.htm</File>
    <File>oric-20230624.xsd</File>
    <File>oric-20230624_lab.xml</File>
    <File>oric-20230624_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d462067d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d462067d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "oric-20230624_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oric-20230624_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "oric-20230624.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "oric",
   "nsuri": "http://www.oricpharma.com/20230624",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d462067d8k.htm",
      "contextRef": "duration_2023-06-24_to_2023-06-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d462067d8k.htm",
      "contextRef": "duration_2023-06-24_to_2023-06-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.oricpharma.com//20230624/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-175501-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-175501-xbrl.zip
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M(QH.&3EU8P+-SN%.>_$Z7PJ[:/G@:FY8Q$5,MNPSHV#Y,!D3=@\]B5#-[$N
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M^JZN\HWF%]':?!$P]WG N5CA,K^".[3>[KOPYY6XXY-PX[W?\B0>D5N@X7/
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M=]0V969O@" '&0WJ@Z;;S ]T;9M3**1C*A6"7>T00BI![N%+P<"T*AM(2#M
M5:DD-8#P[U'Q10%U2Y9@6J]M:[H"T#);_C8YK+8.=JO[3E/[*K+P]:UZE?\$
M&W/P485#[KJ.T"R4\:M;_"K;%8W)#_OPF?I(30_O0@^6"FN-!*L-$J6B)U2@
M.I<SFV6U<]W^FVE/UPZH2['5JA[L[E>==LON&3:67TYA4#,2*<!"K2GF0VU
MI\C4?70C/):LITKRX$TIJ0  FJT4D.LJE_R'O3K*<P66^6'KZNQNR72PM"
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M5@H<#"_JQE([=_.KSP*Y,(*M+_5C38^?0*D%S!LJV]<<3;'2&I$KJ#9T[8;
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M"L+1FV55+=Z4;+5GX#,=N*F_6NZJ:UTQN@U)FV3UY2&ZI#&JY8/>%C?\"+?
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MD75QF9*\D8CLK?J2)SGT/-L]X_<0;EUJIRAI?YH9W8%.PRO1,>U8WBQS# [
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M%#9%FD_[*IN9B5 .762#<2NVP)3?]F,8*'M/Y12\DWH<HP(&D]7*9:9-"BL
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M"QP#PK$B3]&)I+O*2G+/5\5SE$"\P>T,QZ.B$LO6(*LX0;!2L S2RW$:R>.
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M#O,(;@1"@)_X%#=]BKPUC[BF[*#I!HDX<V0S)B>0Z&O(IS(G:X_MB:QFJX)
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MKF]V&&^DP7 .'9+NNTQE*E$D?D>YYCI.G+FPE+>1"H#Y06<Z+DR%8STS3B3
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M.-+C"5%;VH\G+O9+IJ^<=!NR4^V-Y:UD@Q++IAPJ4 #F3:XCN,WKRLVU5XV
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M(SA,$OO,^)4$66]1-YO%);^HL[PUSJ?!O-J^A-.RP+$L<\G:%"2;D3<&38P
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M%&=T^;N6'2C)&V%LKZH)F0RN\DF&54 _FH06E4M,#"OCS)0+X&\,'MUJ0>&
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M&=Y[;<W8GLQ^!=<(ZQL/ST^<D4=7,-71LV?\+DT$8+]$8)]U$%>ZO?Y;6!:
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MMV16ATUC%*%V?^+]CW(M82GSTPQ(0ESP]3.LQR"0":MUC ^6M*7OCA7^ZPA
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M554$<2E9PO'%: )3&1[3;;G2E*<FB#T0X_<*SQ2( A=*7])%K'% 6W+WL[1
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M<P-%^AH2!"SD;DSNTHDO^$"P##AR.2L8KX14&N9S6T#;5Y=8*#=JM_X[*=T
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M_J)><E/Q4".?F/1D]-, 4J)8(P(IBT6RT'>,!-OFO5P\'\8H38\8M82C3.,
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ML]VX[K8O63_(;'N2NYOAQ+=7[<:AG_\ 4$L#!!0    ( *\PVU8LBDD6JP8
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M@OXQ# WYIY(- :_+ !>@"^'"CFV@"G4[%XB8)[\/7XL;P1\H"VK>UBG3> G
MEQDS4?\D%@U]HVY#_*<W-A0Z>37<(6C$2M4DU/"#. XW7,9^]#==U+_':59X
M":-@-F4:A*U(M#$PJ#8T!&DE4*4P[ULV9Z-J *R].'X&4!L4Q*\#_'9.6Y\
M-#7.=X\Y??YO1P<)W.3GO%;&X12_SZW/_EDVZP:B_E!N=#/CK.;]\MV\EH L
M-<#-QUW -&LAP9F(0Z*.==^PF7Z+D-9IV@W4/P6-8\)&?#Y?LNQ^I+2EM22Y
M)62KK?"*(!=X*P21",XJP'8)9XH;;+R(<MWNW7"^XQ$-:$S9])-:<0OJ1[8L
MFS); KG"!"^+<$&X3 V)WT=YR/6=X6VJY2*YM?IVP_9&$#T?1&&1?!)2/QTC
MKN_O[1<.50HM86QABN^+=,%ZGRH2WJH,%.M 6@B22LZ@-VVB"/PSG:"B?RGE
MD@CW 3#HO(PQ*#=H'H:=>,21*-%N:C#2<HW.1T..*J>DEBW'Y0T)EFH]M>D/
M)F,:1];W.';SVEK:E!G@YN-.RQJC%M:B)A,'I0Z)O/N:II%^MU8T-9IV W4L
M?/VH^=UF/N'62_ G22TA:FZ=&PZZP&D00B(S4X94VIG*!AHM(FG;+<YU\WP=
MS)1;4N=A!G-NR]=/HQ%>'H-Q'=W5P[Z6YA5P'F9HKF_C-=6R>8SW]\[G1$S5
MU'P4?!7/U&)DX;.:#_*62+3Z#E^U+;XWU/T]O@I9)-:S-\;R0I!6@JP4TGM\
M#=HPO,E7VPO*"*S53PXFJ;Z;F#X15Y-_0WZ[\)<;XM5Q"-B7:"(SOX;',MEC
MC%C -V3 1+N-B^*.*[6E_[I0MHNF?V-'[?D?4$L#!!0    ( *\PVU;J47<"
MW00   ,N   5    ;W)I8RTR,#(S,#8R-%]P<F4N>&ULU9I=<^(V%(;O=V;_
M@^K>M#,UYB/))DS(#B5)AVF^AK!MIS<[PCZ IK+DD42 ?]\C@UH,)@O9;<?*
M10!;[]%[SB.$)?ORXR+EY 649E)T@D:M'A 0L4R8F'2"F0ZICAD+B#94))1+
M 9U@"3KX>/7^W>5W84BN;_L/)"138S+=CJ+Y?%Y+QDQHR6<&0^I:+-.(A*%K
MWQM^(K^MNFN3 7"@&DA*M0%%?IXQGK2;]6:ST:B?U\XV90JHC4<2:J!-SJ+F
MAP@;MLAYNUYOGUZ0[CVYR:,(,F0I;$IEME1L,C7DA_A'DHNNI1# .2S)+1-4
MQ(QR\NP<_T3Z(JZ1+N=D8&4:;6I0+Y#4UE$Y$W^U[;^1-4_>OR/XAW44.C_:
M"6PUUL58C!2O235!M_56Y$3!IF:Q(YJW<DGCXN(BRL\6VVM6UAH[:$1_W-\]
MQU-(:8@,D%F\U16Z2<P_ZDUSI]'JI&NO65OGD>YDG)?^@+3(WA;V4^B:A?90
MV&B&K49MH9/@RG:YJJJ2' 8P)O;UTZ!?Z%,J%F=3JE*:#ZJ<?_VL>1(9NI!"
MILO(JJ)K&<]2$,:]=D5R(PPSR[X82Q3;7 *2E[4]53#N!#9PZ*)91]\/,-#G
M8P*998;?#,W2C$- HHV,,H6C1YB\]1T>* A@84 DD+@P-H'_+.>K%=GU\)5Q
MH0;N"YQCTQ#7)O(E2H#9'IOVC2U0,R\.?OC<DSAG=$?:*!J;8A&X'2]2N8.<
MCH!W@A)1]"T-=3'MQ*9^R^GD4$-;HJ*A37!=%1="4A6[</AVAUIQ[*];1!E5
M&"^,ISC+.?58R;2T..O>9*E1J1)0G0#3Q^]\0#+%<)R8)1X)R$RC%YE9UY3;
M<S &I2"Y6Z6]UV5N$>=/#7G+;XQG-1I[F(&BO(]#?O$K+ _%M$=<75Q[##ML
M+6^PN?EDB&4\E%914UU(19^.S:EW;)X O>)TGUSCI=&QD+;$U:>U9=AA._,&
MVVIN&,"$V42%>:#IP=3*M=6%5N[7,?O@&3-<%DB52967]ADK##TYPRE^V9/)
MD0B_$*KJ1+]@WP$^]PSP+>/P,$M'H(ZCN:FK.KI-KX[3A6><AG313[ ,;,Q6
M2].W0-L;I.H$]QI?XVS5/</931(LLEZ_X!H9&L>A+ U0=8REIAW"AO<(FU^+
ML.DCPN:_"'U;FZ^SZ.';1S64<_$F@)MR3_!M6G;P_%FA%U+)+\4>U9.2+\QN
M_;Z%X$X,3S#N^'8L3_QD^22UH?Q/EAV_NBB/X G'+=>.HC_[,G8^Z2J@QW K
M:JI+JNC3L?%G\\7>R^)/4RF.7.?MZJK+:->KX^3/ALOOZ,^ Z,DTG8GU,D<?
M"FN/N+K$]AAVV/S91GF6G,7,,#&YQQ]CQ:RUPYB5*:L+K,RMH^7/9LJ3 COD
M *^6\OL@]DZT>AR/#Y\67XM077JON5Y3//%G#V4KF[[6,U!?S[(DCC=$2[P[
MKOYLK#Q#/+,6&\W1D!E^\*7DKJZZW':].D[^[)X,%;4/RSTOTY$\^.=N2U1=
M0EM&'1Y_]D?<$+M9Q%,J)G#,[=9R;75AE?MUS'S;![E)04UP[/VBY-Q,<7[/
MJ#CRD:$](:I+\%7;#J0_6R'K=!8XBPC-K+G5XQM'4BS15QYAB6?'[W_8+KF,
M=NIRAP?LP\NK,_:??107C_P-4$L! A0#%     @ KS#;5H\(^B17&   9(H
M  X              ( !     &0T-C(P-C=D.&LN:'1M4$L! A0#%     @
MKS#;5NO2*_DA@0  ^IX" !$              ( !@Q@  &0T-C(P-C=D97@Q
M,#$N:'1M4$L! A0#%     @ KS#;5O9/!)7%.0  $?   !
M ( !TYD  &0T-C(P-C=D97@T,2YH=&U02P$"% ,4    " "O,-M68@VC KD3
M  "V00  $0              @ '&TP  9#0V,C V-V1E>#DY,2YH=&U02P$"
M% ,4    " "O,-M6L1R;I4 #  !2"P  $0              @ &NYP  ;W)I
M8RTR,#(S,#8R-"YX<V102P$"% ,4    " "O,-M6+(I)%JL&  "D20  %0
M            @ $=ZP  ;W)I8RTR,#(S,#8R-%]L86(N>&UL4$L! A0#%
M  @ KS#;5NI1=P+=!    RX  !4              ( !^_$  &]R:6,M,C R
C,S V,C1?<')E+GAM;%!+!08     !P ' +T!   +]P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
